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Abstract

STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF BUPROPION AND RELATED
3-SUBSTITUTED METHCATHINONE ANALOGUES AT MONOAMINE
TRANSPORTERS
By Abdelrahman Shalabi Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2017

Major Director: Dr. Richard A. Glennon
Professor
Department of Medicinal Chemistry

The khat plant, catha edulis, has been abused for some time in the Middle East and the
African horn for its short-term stimulant effects. However, it was not until 1975 when
cathinone, β-ketoamphetamine, was identified as the major stimulant component of khat.
Structural analogues of cathinone, synthetic cathinones, are new psychoactive
substances available on the clandestine market of numerous countries including the USA.
Abuse of these new illicit stimulants is a worldwide growing health concern which
necessitates the investigation of the pharmacological properties of these new drugs of

xvi
abuse. The abuse liabilities of these compounds seem to be related to the three major
monoamine transporters (MATs): the dopamine, norepinephrine, and serotonin
transporters (DAT, NET, and SERT, respectively). Synthetic cathinones act as either
releasing agents by stimulating the release of the presynaptic neuronal content of
neurotransmitters, or as reuptake inhibitors by inhibiting normal physiological reuptake of
neurotransmitters from the synaptic cleft. Bupropion (DAT/NET reuptake inhibitor) is
clinically prescribed for the treatment of depression and smoking cessation, whereas its
closely related cousin, cathinone (DAT/NET releasing agent), is a drug of abuse.
Deconstruction of bupropion (i.e., a stepwise conversion – or structural transition – of
bupropion to cathinone) and investigation of the actions of the deconstructed analogues
at the three major MATs showed that the steric bulk at the terminal amine controls the
molecular mechanisms of these compounds at MATs (i.e. reuptake inhibition versus
substrate-induced release). This study also concluded that bupropion is abused, because
it is a cathinone derivative. Methcathinone (MCAT), N-methylcathinone, (DAT/NET
releasing agent) is a recreational street drug and a US Schedule I substance; however,
new MCAT analogues are continually appearing on the clandestine market to circumvent
prosecution under the Controlled Substance Analog Enforcement Act. We investigated
the actions and structure-activity relationships of a series of 3-substituted MCAT
analogues at MATs and their quantitative structure-activity relationships to determine the
physicochemical properties of the 3-position substituents important for the releasing
actions of these compounds. This study indicated that the steric bulk of the 3-position
substituents controls the selectivity of these compounds at MATs.

I. Introduction

Abuse of synthetic cathinones, structural analogues of cathinone, is an emerging public
health concern in the US and Europe.1 Synthetic cathinones, designer drugs, are
designed by clandestine chemists to mimic the stimulant effects of controlled drugs of
abuse, such as amphetamine and cocaine, and to avoid the legal penalties associated
with using them. These illicit stimulants are distributed by drug dealers, adult book stores,
smoke shops, gas stations, and internet retailers and may be administered by ingestion,
insufflation, and/or injection.2 Short-term favorable effects, such as euphoria, sexual
arousal, talkativeness, and empathy, are responsible for the great abuse potential of
cathinone derivatives, but the cardiovascular and neurologic symptoms associated with
the acute administration of these derivatives may be fatal. 1,2 The rapidly increasing
number of poison control center calls and drug reports to the National Forensic Laboratory
Information System (NFLIS) about synthetic cathinones in the USA as well as the high
number of synthetic cathinones (>150 cathinone derivatives) found on the clandestine
market in the last several years point to the urgent need to study the pharmacological
properties of these new psychoactive substances.1,2

1

II. Background

A. Bupropion
Bupropion (marketed as Wellbutrin® or Zyban®) (1; Figure 1) is a clinically prescribed
medication for the treatment of depression, smoking cessation, obesity, attention deficit
hyperactivity disorder (ADHD), bipolar disorder, and sexual dysfunction. 3,4 Although
bupropion is effective, as are the commonly used selective serotonin reuptake inhibitors
(SSRIs), Zoloft® and Prozac®, for the treatment of depression and does not give rise to
the undesirable obesity or sexual dysfunction caused by these agents, it is not a first-line
antidepressant medication because of its high abuse liability.4,5 Unfortunately, bupropion
is abused for its CNS stimulant effect primarily caused by its action at dopamine
transporters; it may be obtained by deceiving clinicians or purchased from the clandestine
market ($2–3 per 100 mg).4,6,7 The pills are usually crushed and snorted, but can be also
ingested orally in doses higher than the clinically prescribed doses or dissolved in water
and injected intravenously.4 Structurally, bupropion might be viewed as a synthetic
cathinone (Figure 1). Cathinone (2; Figure 1) is a recreational drug of abuse and a
controlled substance (US Schedule I).1 In contrast, bupropion is a clinically prescribed
medication.3 Here, we examine the structural transition from bupropion to cathinone to
better understand their actions.

2

1

3

2

4

Figure 1. Chemical structures of bupropion (1), cathinone (2), methcathinone (3), and
amphetamine (4).

B. Methcathinone
The substance now known as methcathinone (MCAT) (3; Figure 1), N-methylcathinone,
was originally developed as a potential cardiovascular and analeptic agent, but it ended
up being a recreational street drug because of its CNS stimulant effect.1 The drug is
available on the clandestine market of numerous countries including the USA under the
street names Jeff or Cat and is usually administered by insufflation (snorting) or I.V.
injection.1,8,9 The stimulant action of MCAT was coincidently uncovered in 1962;10
however, it was not until 1987 when Glennon et al.11 characterized N-methylcathinone as
a potent and new amphetamine–like agent and named it methcathinone by analogy to
methamphetamine (N-methylamphetamine). In the early 1990s, MCAT was classified as
a Schedule I substance by the US government.1 Although MCAT is a Schedule I
stimulant, new MCAT analogues are continually appearing on the clandestine market to
circumvent prosecution under the Controlled Substance Analog Enforcement Act.2,12

Quantitative structure-activity relationship (QSAR) studies are extremely helpful tools to
uncover the pharmacological properties of derivatized MCAT in a cost-wise manner
without having to test them all one at a time. A QSAR study of 4-substituted MCAT
3

analogues was conducted in response to the wide availability of these derivatives on the
clandestine market.13

Synthetic cathinones are structural analogues of cathinone, the β-keto analogue of
amphetamine (4; Figure 1) which is originally derived from a natural source;14 S()cathinone (S(-)2; Figure 1), the naturally occurring cathinone, is the major stimulant
component of the shrub catha edulis (khat).14 Interestingly, khat has been used and
abused for some time in the Middle East and the African horn.15

C. Khat plant
Khat was first scientifically described in 1775 by the Swedish botanist Peter Forsskal who
named it as catha edulis, which implies that the plant is edible.16 It also has numerous
common names such as qat, chat, jaad, miraa, African salad, Abyssinian tea, Bushman’s
tea, and flower of paradise.17 The khat tree is evergreen with reddish stems, green leaves,
and white flowers that belongs to the Celastraceae family of plants.14 The plant, originally
indigenous to Yemen and Ethiopia, is also cultivated in East Africa, South Africa,
Madagascar, and Afghanistan.14 It is usually served in these countries to welcome guests
in social events, such as wedding ceremonies or burials, as a part of their cultures,
because

it reduces fatigue

and

hunger

sensation

and

improves

alertness,

communication, and self-confidence.18-20 Additionally, khat is traditionally used for the
treatment of respiratory disorders, stomach problems, cough, and influenza. 21-23
Interestingly, it has been shown that khat leaves have antimicrobial, anticarcinogenic,
antioxidant, antidepressant, and aphrodisiac properties, and reduce blood glucose,

4

triglycerides and cholesterol levels.19,24-28 Although khat may be used for the treatment of
several medical conditions, it may also be abused for its stimulant effects. Amphetaminelike pharmacological effects, such as euphoria, alertness, anorexia, increased sensory
stimulation, hyperthermia, increased respiration and heart rates, and elevated blood
pressure, have been reported after khat administration.29-31 Chewing khat leaves is the
most common way of administration; they also may be smoked or consumed as
drinks.19,32 It has been reported that there are approximately 100 million global khat
abusers who consume khat leaves on a daily basis; and 5–15% of the population in some
of the eastern African countries are khat dependent.33,34 The legal status of khat is
controversial, because its consumption is prohibited in some countries and allowed in
other countries. Khat use is illegal in all European countries except Portugal and the UK,15
where khat is considered as a natural product. Unfortunately, banning khat use is
extremely difficult in countries which are culturally and economically dependent on khat
consumption.35

Uncovering the active constituent responsible for the CNS stimulant effect of khat was a
great puzzle. Flueckiger and Gerock suspected caffeine (5; Figure 2) to be the active
ingredient of khat, but they found out that the stimulant action of khat is likely to be caused
by another alkaloid which was named as katin.14 Wolfe then isolated katin from khat
leaves and determined its structure as (+)norpseudoephedrine (cathine) (6; Figure 2);14
however, the weak stimulant action of cathine could not explain the strong stimulant effect
observed after khat consumption. An alkaloid with a strong CNS stimulant action was first
isolated by Brilla,14 but he could not determine its structure. Finally, a research team at

5

the United Nation’s Narcotics Laboratory determined the structure of this alkaloid as S()cathinone (S(-)2; Figure 1) which is primarily responsible for khat abuse.14

5

6

Figure 2. Chemical structures of caffeine (5) and cathine (6).

D. Overview of transporters
It has been shown that the stimulant effects of S(-)cathinone (S(-)2; Figure 1) and
synthetic cathinones are related to their actions at monoamine transporters (MATs). 1,2
Transporters play biologically important roles in cell homeostasis by controlling uptake
and efflux of numerous biochemically essential molecules, such as inorganic ions, amino
acids, sugars, nucleotides, and drugs, across biological membranes; and they are
assumed to constitute 10% of the human genome.36 Disorders of membrane transport
are associated with numerous diseases. Transporters also affect the pharmacokinetic
and toxicological profiles of drugs; thus, the FDA requires the evaluation of transporters
in drug development processes.37

According to the transporters classification database (TCDB) approved by the
international union of biochemistry and molecular biology (IUBMB), transporters are
classified into channels or pores, primary active transporters, group translocators,
transmembrane electron carriers, and electrochemical potential-driven transporters.38
Channels or pores catalyze the energy-independent facilitated diffusion of solutes
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according to their electrochemical gradients without following a carrier mediated
mechanism.38 Primary active transporters utilize a primary energy source to transport
solutes against their concentration gradients.38 Group translocators chemically modify
substrates during transport processes.38 Transmembrane electron carriers control
membrane potential and cellular energetics by exchanging electrons between donors and
acceptors on opposite sides of the membrane.38 Electrochemical potential-driven
transporters are characterized by a carrier mediated mechanism; they are usually called
secondary carriers because they never utilize a primary source of energy. 38 Porters
constitute the major subclass of this class of transporters. Porters are divided into
uniporters, antiporters, and symporters.38 In uniporters, only one species can be
transported; and the process of transport is driven by either facilitated diffusion or
membrane potential.38 Antiporters and symporters utilize the chemiosmotic source of
energy to transport two or more species in opposite directions or the same direction
respectively.38 The porters subclass of transporters is divided into 127 families including
neurotransmitter: sodium symporter (NSS) family, which is primarily responsible for cotransportation of neurotransmitters or amino acids along with sodium ions and/or other
ions such as potassium and chloride ions.38 Members of NSS family include the creatine
transporter, γ-Aminobutyric acid (GABA) transporters, the glycine transporter, and MATs.

A commonly used system for classification of transporters is the solute carrier (SLC)
system, which classifies transporters into SLC and non SLC superfamilies. The SLC
superfamily includes secondary active transporters (coupled transporters), passive
transporters, vesicular transporters, and mitochondrial transporters; the non SLC
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superfamily includes ion channels, water channels, and primary active transporters.36 The
SLC superfamily is divided into 52 families including the SLC6 family. It is noteworthy that
members of SLC6 family are also members of NSS family. In humans, SLC6 transporters
are expressed in kidney, intestine, nervous system, pancreas, adrenal gland, and testis.39
They play physiologically important roles in absorption and reabsorption of amino acids
and osmoylates by intestine and kidney respectively; and they are also located at
presynaptic neurons of the central and peripheral nervous system for clearance of
neurotransmitters or amino acids as well as termination of their actions.39 Additionally,
they are required for spermatogenesis by testis.39 Dysfunction of SLC6 transporters is
associated with numerous diseases and pathological conditions such as orthostatic
intolerance, ADHD, addiction, osmotic imbalance, X-linked mental retardation, Hartnup
disorder, hyperekplexia, Tourette syndrome, schizophrenia, Parkinson disease (PD),
autism, mood disorders, obsessive compulsive disorder (OCD), and post-traumatic stress
disorder (PTSD).39

E. MATs
1. Biological functions and CNS localization
The three major MATs, dopamine, norepinephrine, and serotonin transporters (DAT,
NET, and SERT, respectively), belong to both NSS and SLC6 families of transporters and
are responsible for termination of neurotransmission in monoaminergic neurons
(dopaminergic, adrenergic, and serotonergic neurons, respectively), by reuptake of
released neurotransmitters from synapses into the presynaptic neurons, where they are
stored in synaptic vesicles for subsequent release upon stimulation.39,40 Dopamine
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transporters are responsible for the reuptake of dopamine (DA) (7; Figure 3) in
dopaminergic neurons. Dopaminergic innervations are present in different regions of
mammalian CNS (Figure 3) and play different biological roles according to their CNS
locations. Dopaminergic neurons that originate from the substantia nigra to the dorsal
striatum are extremely important for controlling of voluntary motor movements; and
degeneration of these neurons gives rise to PD.41 On the other hand, dopaminergic
neurons originating from the ventral tegmental area (VTA) are involved in motivation,
reward, and reinforcement; dysfunction of these neurons is associated with addiction. 41
Norepinephrine transporters terminate signal transduction in noradrenergic neurons by
reuptake of norepinephrine (NE) (8; Figure 3). Noradrenergic neurons project from locus
coeruleus in the brain stem to a variety of forebrain regions in CNS (Figure 3) and regulate
sleep and wakefulness, attention, as well as feeding behavior. 41 Serotonin transporters
located at presynaptic serotonergic neurons are responsible for reuptake of serotonin (5HT) (9; Figure 3). Serotonin releasing neurons extend from raphe nuclei to different
forebrain regions in the CNS (Figure 3) and regulate sleep and wakefulness; dysfunctions
of serotonergic networks in mammalian CNS give rise to mood disorders such as
depression and anxiety.41 Wide expression of monoaminergic neurons in the CNS points
to the roles of MATs in regulation of the aforementioned physiological processes and the
therapeutic benefits that might be obtained by targeting these transporters.
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Figure 3. Structures of DA (7), NE (8), and 5-HT (9) along with the corresponding
CNS neuronal networks.41
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2. Structure and topology
Structural information about human monoamine transporters (hMATs) is usually obtained
from other members of NSS or SLC6 families having reasonable amino acid sequence
similarities due to lack of high resolution X-ray crystallographic structures of hMATs. The
structure of hSERT in the open-to-out conformation, reported in 2016, is the only available
X-ray crystallographic structure of an hMAT; recent structures of Drosophila
melanogaster dopamine transporter (dDAT), an eukaryotic DAT, are also available in
open-to-out and occluded conformations.42-44 However, most of the literature studies of
hMATs are based on the structure of prokaryotic leucine transporter (LeuT) from Aquifex
aeolicus, because it was reported 8 years before resolving the structure of the first
eukaryotic monoamine transporter.44,45 Additionally, LeuT shares 20-25% sequence
identity with hMATs and is available in open-to-out, occluded, and open-to-in
conformations, which allowed visualization of the whole transport cycle.45-48 Therefore,
homology modeling of hMATs based on LeuT or dDAT structures and molecular
dynamics (MD) simulations coupled with site-directed mutagenesis and biochemical
assays are the major sources of structural information about hMATs. The amino acid
sequence homology of hSERT with hDAT and hNET are 49% and 50% respectively;
hNET has 67% sequence identity with hDAT.49 Therefore, amino acid sequence
alignment of these transporters is an excellent technique to predict conserved amino acid
residues involved in closely related functions.

According to the X-ray crystallographic structures of LeuT, hSERT, and dDAT, hMATs
are assumed to have 12 transmembrane-spanning domains (TM1–12), intracellular C-
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and N-termini, 5 intracellular loops (IL1–5), and 6 extracellular loops (EL1–6) (Figure 4).
The arrangement of TMs (TM1–5) is the same as that of TMs (TM6–10), which is known
as pseudo-symmetric fold or the LeuT-fold (Figure 4).40

Figure 4. Overall topology of MATs.40

3. Mechanism and transport cycle
The synaptic content of monoamines is lower than that of the presynaptic neurons;
therefore, MATs utilize a secondary source of energy to transport neurotransmitters
against their concentration gradients by coupling transport of substrates to transport of
Na+ and Cl- ions along their concentration gradients.50 Moreover, counter-transport of K+
ion is also required only by hSERT.51 In hDAT, DA is co-transported with 2 Na+ ions and
1 Cl- ion.50 In hNET, NE is co-transported with 1 Na+ ion and 1 Cl- ion. 50,52 In hSERT, 5HT is co-transported with 1 Na+ ion, 1 Cl- ion, and 1 K+ ion.50,53 The molecular mechanism
of MATs is not fully understood; however, the availability of the X-ray crystallographic
structures of NSS family members in different conformations (Figure 5) in combination
with MD simulations allowed the visualization of the transport cycle of MATs. The
transport cycle of MATs was explained by three mechanisms: the alternating access
mechanism, the rocking bundle transport mechanism, and the two-substrate
mechanism.54-56 In the alternating access mechanism, it is assumed that there is only one
12

substrate binding site formed by TM1, TM3, TM6, and TM8 and located in the center of
the transporter; the transporter alternates between different conformations to make the
binding site accessible from both the extracellular and the intracellular sides.40,54 In the
rocking bundle transport mechanism, TM3–5 and TM8–10 are considered as a stationary
scaffold surrounding a rocking bundle of TM1, TM2, TM6, and TM7 which rock back and
forth allowing the transporter to alternate between different conformations (Figure 5). 40,55
The transporter picks up its substrate in the outward open conformation and shifts to the
outward occluded conformation by closing the extracellular gate/gates; and it then
changes its conformation to the inward occluded conformation followed by opening the
intracellular gate/gates to release the substrate.40,55 The two-substrate mechanism
suggests that the transporter has additional secondary substrate binding site located at
the extracellular vestibule; and occupation of this site by an additional substrate molecule
is required to trigger opening of the intracellular gate and release of the substrate from
the primary binding site.40,56 The alternating access and the rocking bundle mechanisms
of transport are more reasonable than the two-substrate mechanism, because the X-ray
crystallographic structures of NSS family members have been obtained in different
conformations which suggest that the transporters interconvert between these
conformations to facilitate the transport processes.57 Additionally, these transporters have
never been co-crystallized with two substrate molecules; therefore, there is no visual
evidence supporting the two-substrate mechanism.57
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Figure 5. Rocking bundle transport mechanism.40
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F. Vesicular monoamine transporters (VMATs)
1. Biological function and CNS distribution
The functions of VMATs are complementary to those of MATs. Once the
neurotransmitters are delivered to the cytoplasm of the presynaptic neuron by MATs, they
are transported to the cytoplasmic vesicles by the VMATs located at the vesicular
membranes to protect them from metabolism by the cytoplasmic monoamine oxidase
(MAO).58 Storage of neurotransmitters in the cytoplasmic vesicles of presynaptic neurons
is a critical step in monoamine neurotransmission; the neurotransmitters can then be
released into the synapses upon stimulation of the presynaptic neurons.58 There are 2
types of VMATs, VMAT1 and VMAT2; however, only VMAT2 is expressed in CNS and is
the transporter responsible for uptake of cytoplasmic NE, DA, and 5-HT in noradrenergic,
dopaminergic, and serotonergic CNS neurons respectively.58,59

2. Structure and transport mechanism
The X-ray crystallographic structures of VMATs are not resolved; therefore, amino acid
sequence alignment to related proteins was used to predict the topology of these
transporters. The 3D structures of VMATs are expected to be similar to those of MATs;
they probably have 12 transmembrane-spanning domains (TM1–12) with cytoplasmic Cand N-termini.58 Interestingly, VMATs belong to a family of transporters different than that
of MATs (SLC18) and follow a different transport mechanism; VMATs are proton-coupled
antiporters which utilize the vesicular content of protons accumulated by the action of
vacuolar ATPase as a secondary source of energy to co-transport one substrate molecule
and two protons in opposite directions.60 The vesicular concentration of biogenic amines
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is 10,000 times higher than the corresponding cytoplasmic concentration which points to
the efficacy of VMATs and their important physiological roles in vesicular storage of
monoamines.60

G. Mechanisms of action of synthetic cathinones
Cathinones are β-ketoamphetamine analogs (Figure 1); and both cathinones and
amphetamine belong to a general chemical class called phenylalkylamines.1,15 The
actions of stimulant phenylalkylamines at MATs are primarily responsible for the
pharmacological profiles and the abuse potential of these compounds.15,61 Stimulant
effects, primary causes of abuse of synthetic cathinones, euphoria, and sexual arousal
experienced after consumption of synthetic cathinones, are mediated by their actions at
DAT; talkativeness and empathy are also experienced as a result of their actions at
SERT.15,61 However, the undesirable cardiovascular effects of these compounds are likely
to be associated with their actions at NET.15,61 Pharmacological characterization of
cathinone derivatives started with identification of cathinone (2; Figure 1) and MCAT (3;
Figure 1) as amphetamine-like agents that act primarily as releasing agents at DAT;11,62
however, methylenedioxypyrovalerone (MDPV) (10; Figure 6), a widely abused synthetic
cathinone, was later characterized as a cocaine-like agent that acts as a DAT reuptake
inhibitor.63 Therefore, synthetic cathinones could be classified according to their actions
at MATs into either amphetamine-like releasing agents or cocaine-like reuptake
inhibitors.15,64
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Figure 6. Chemical structures of MDPV (10), methylone (11), mephedrone (12), αPVP (13), and pyrovalerone (14).

1. Releasing agents
Amphetamine stimulates the release of monoamines from the presynaptic neurons into
synapses by reversing the directions of both MATs and VMAT2. 57 First, amphetamine is
transported by MATs into the presynaptic neurons. Second, it is picked up by VMAT2 into
the synaptic vesicles, where it alkalinizes their contents, dissipate the proton gradient,
and stimulate the outward transport of neurotransmitters to the cytoplasm (weak base
hypothesis); amphetamine also inhibits the cytoplasmic MAO which further enhances the
cytoplasmic pool of monoamines.57 Finally, the neurotransmitters are released from the
cytoplasm to the synapses by the action of MATs. Obviously, amphetamine is an
exogenous MAT substrate that depletes the presynaptic content of neurotransmitters;
thus, releasing agents are also called transporter substrates. It should be taken into
consideration that amphetamine also acts as a reuptake inhibitor, because it competitively
inhibits the uptake of monoamines by both MATs and VMAT2; however, its releasing
potency is much higher than its potency as a reuptake inhibitor. 57,58,64,65 It is noteworthy
that releasing agents can act as reuptake inhibitors, but reuptake inhibitors cannot act as
releasing agents.64 Amphetamine-like synthetic cathinones, such as cathinone (2; Figure
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1), MCAT (3; Figure 1), methylone (11; Figure 6), and mephedrone (12; Figure 6), also
act as releasing agents by reversing the directions of MATs and VMAT2.64,66

2. Reuptake inhibitors
Cocaine also elevates the synaptic concentrations of neurotransmitters, but it follows a
totally different mechanism. Cocaine inhibits the normal physiological uptake of DA from
synapses by DAT resulting in elevated synaptic DA concentration, overstimulation of
postsynaptic receptors, and prolongation of dopaminergic neurotransmission.67 Similarly,
cocaine-like synthetic cathinones inhibit the reuptake of monoamines by MATs; it is
noteworthy that some cathinone derivatives are even more potent DAT inhibitors than
cocaine itself.68 Cathinone derivatives which act via a reuptake inhibition mechanism
include bupropion (1; Figure 1), MDPV (10; Figure 6), α-pyrrolidinovalerophenone (αPVP) (13; Figure 6), and pyrovalerone (14; Figure 6).3,68

3. Bupropion
Bupropion (1; Figure 1) is used as antidepressant.69 Bupropion acts as a DAT/NET
reuptake inhibitor (Table 1),3 but it is extensively metabolized by 1st pass metabolism as
evidenced by excretion of about 85% of its oral dose in urine of rats and humans resulting
in poor oral bioavailability.69

Table 1. Uptake IC50 values of bupropion in comparison to its major metabolite at
DAT and NET.70
Compound
Bupropion (1)
(2RS,3RS)Hydroxybupropion ((2RS,3RS)16)
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DAT
(IC50) nM
550
>10000

NET
(IC50) nM
1900
1700

In humans, bupropion is predominantly metabolized by hydroxylation of one of its methyl
groups to give the proposed intermediate 15 that could not be isolated; the unisolated
bupropion metabolite 15 then undergoes cyclization to create an additional chiral center
and yields only the trans-diastereomers, (2RS,3RS)hydroxybupropion ((2RS,3RS)16)
(Figure 7).69 These trans-diastereomers also contribute to the antidepressant mechanism
of bupropion by acting as NET reuptake inhibitors (Table 1).70 Unlike the transdiastereomers, the cis-diastereomers, (2RS,3SR)hydroxybupropion ((2RS,3SR)16),
could not be isolated from human plasma because of the steric hindrance that creates a
high energy barrier against the cyclization reaction required for their de novo synthesis.69

*

*

1

15

* *
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Figure 7. Metabolism of bupropion.69

The metabolic profile of bupropion explains its therapeutic/abuse potential and is greatly
affected by routes of administration.4 Clinically prescribed bupropion is administered
orally in therapeutic doses and is susceptible to extensive 1st pass metabolism resulting
in poor oral bioavailability (5%–20%); thus, it has been suggested that the low plasma
concentration of bupropion obtained upon oral administration is sufficient to produce its
therapeutic effects and insufficient to produce the stimulant effects caused by other
synthetic cathinones.4 However, repeated oral administration of bupropion or
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administration by other routes that by-pass the 1st pass effect, such as I.V. injection or
inhalation (snorting), increases its plasma concentration resulting in euphoria and
stimulant like effects.4

H. SAR of cathinones at MATs
Knowledge about the structural features of synthetic cathinones critical for their
pharmacological actions at MATs and the physicochemical properties of the aromatic
substituents that significantly contribute to these actions not only enhances our
understanding of the molecular mechanisms of actions of these new psychoactive
substances which determines the abuse liabilities of these compounds and provides the
drug enforcement agency (DEA) with extremely important pieces of information, but also
uncovers interesting pharmacological properties that may be utilized for therapeutic
purposes. Structure-activity relationship (SAR) studies on synthetic cathinones at MATs
are conducted to determine the structural features that differentiate between releasing
agents and reuptake inhibitors and significantly affect the releasing potencies or reuptake
inhibition values of these compounds, respectively. Additionally, the physicochemical
properties of aromatic substituents, such as electronic character (σ), lipophilicity (π), or
steric bulk (ES), that contribute to the actions of these compounds as releasing agents or
reuptake inhibitors or affect their selectivity at MATs are also studied. Most of the available
SAR studies in the literature are based on in vivo locomotor stimulant and drug
discrimination studies in rodents which are greatly affected by the pharmacokinetics of
different cathinone analogues; the in vitro MAT profiles of cathinone derivatives are not
thoroughly investigated. Investigation of the in vitro MAT profiles of these agents provides
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more accurate data and is a great tool to differentiate reuptake inhibitors from releasing
agents. It is not surprising that most of the SAR studies on synthetic cathinones at MATs
focus on DAT, because it underlies the stimulant effects and abuse potential of these
compounds. However, investigation of the actions of cathinone derivatives at other MATs
(SERT and NET) is also crucial to determine the structural features responsible for other
pharmacological properties mediated by these transporters.

1. SAR of releasing agents
The structural features of cathinone, a prototypical releasing agent, that are worthy of
investigation include the stereochemistry of its chiral center (a), the α-methyl group (b),
the terminal amine (c), the carbonyl group (d), and the aromatic substituents (e) (Figure
8). This has been recently reviewed.71

Figure 8. SAR of cathinone at MATs.71

It is well known that racemic cathinone (2; Figure 1) is a DA releasing agent; therefore,
the individual enantiomers were tested for their releasing potencies at MATs. 71
S(−)Cathinone (S(-)2; Figure 1) is 5 to 7 times more potent than R(+)cathinone (R(+)2;
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Figure 1) as a releasing agent at DAT and NET; however, both isomers are inactive at
SERT (Table 2).71

Table 2. Releasing potencies of cathinone isomers at MATs.71
Compound
S(−)Cathinone (S(-)2)
R(+)Cathinone (R(+)2)

DAT
(EC50) nM
25
184

NET
(EC50) nM
14
72

SERT
(EC50) nM
9267
>10000

Removal of the α-methyl group of racemic cathinone (2; Figure 1) (EC50 = 83 nM) results
in 3-fold decrease in its releasing potency at DAT; however, α-desmethylcathinone (17;
Figure 9) (EC50 = 208 nM) is still active as a DA releasing agent.71 Hence, the α-methyl
group is not important for the releasing action of cathinone at DAT.

17

18

19

20

Figure 9. Structures of α-desmethylcathinone (17) and phenylpropanolamines
(18–20).

A primary amine is optimal for the releasing potency of cathinone analogs at DAT;
however, N-methylation is tolerated.71

Removal of the carbonyl group of S(−)cathinone (S(-)2) yields S(+)amphetamine (S(+)4;
Figure 1) which is approximately equipotent as a releasing agent at MATs (Table 3);
however, reduction of the carbonyl group of cathinone to a hydroxy group yields a mixture
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of 4 phenylpropanolamines: (+)pseudonorephedrine or cathine (6; Figure 2),
(−)norephedrine

(18;

Figure

9),

(+)norephedrine

(19;

Figure

9),

and

(-

)pseudonorephedrine (20; Figure 9) which act as weak DA and/or NE releasing agents
(Table 3).66,71

Table 3. Releasing potencies of S(−)cathinone (S(-)2), S(+)amphetamine (S(+)4),
cathine (6), and phenylpropanolamines (18–20) at MATs.66,71
Compound
S(−)Cathinone (S(-)2)
S(+)Amphetamine (S(+)4)
Cathine (6)
(−)Norephedrine (18)
(+)Norephedrine (19)
(-)Pseudonorephedrine (20)

DAT
(EC50) nM
19
25
68
302
1371
294

NET
(EC50) nM
12
7
15
42
137
30

SERT
(EC50) nM
2366
1765
Inactive*
Inactive*
Inactive*
Inactive*

*Inactive

means that 10000 nM of the test compound could not evoke
>30% of maximal release.

The physicochemical parameters of aromatic substituents that significantly affect the
potencies of releasing agents at MATs have not been thoroughly investigated. 71 4Substituted analogues (Figure 8) usually have lower potency at DAT; the nature of the
substituent also controls SERT/DAT selectivity.71 The higher the steric bulk of the
substituent at the 4-position of the ring, the higher the SERT/DAT selectivity of releasing
agents.71

It can be easily concluded from the previous SAR studies that MCAT (3; Figure 1) is a
releasing agent at MATs. MCAT is a Schedule I stimulant drug of abuse that acts as a
selective DAT/NET releasing agent.2,12,71 Derivatization of MCAT is a technique followed
by clandestine chemists to escape prosecution under the Controlled Substance Analog
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Enforcement Act; the only way of derivatization that does not substantially change the
structure of MCAT is to prepare ring-substituted analogues of MCAT. Actually, numerous
3- and 4-sustituted MCAT analogues have been reported on the clandestine market;1,13,72
2-substituted MCAT derivatives are likely to be the final destination of the clandestine
chemists in their trip of MCAT derivatization. However, 3- and 2-substituted MCAT
analogues have yet to be systematically investigated.

The most comprehensive SAR study on 4-substituted MCAT analogues at MATs was
conducted by Sakloth et al.13 who investigated the physicochemical properties of the 4position substituents that significantly contribute to the potency and/or selectivity at
different MATs. In this study, MCAT (3) and six 4-substituted MCAT analogues were
prepared and tested for releasing potency at MATs (Table 4).13,73,74 A negative correlation
was obtained between the potency of these compounds at DAT and the volume as well
as the maximal width of the 4-position substituent.13,73,74 On the other hand, increasing
the volume or the length of these substituents enhanced the potency of the 4-substituted
MCAT analogues at SERT.13,73,74 Therefore, it is not surprising that the maximal width
and the volume of the 4-position substituents was correlated with DAT/SERT selectivity
of these compounds.13,73,74 Moreover, the hydrophobic character of the 4-position
substituent also contributes to the potency of these analogues at SERT, but not DAT and
NET.13,73,74 Interestingly, the EC50 values of these compounds at DAT strongly correlate
with the corresponding EC50 values at NET, but neither correlate with EC50 values at
SERT;74 these data suggest that this class of compounds acts similarly at DAT and NET
to release DA and NE, respectively.
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Table 4. Releasing potencies of racemic MCAT (3) and 4-substituted MCAT
analogues at MATs.13,74

Compound

R

MCAT (3)
4-CH3 MCAT (12)
4-F MCAT (21)
4-OCH3 MCAT (22)
4-Cl MCAT (23)
4-Br MCAT (24)
4-CF3 MCAT (25)

H
CH3
F
OCH3
Cl
Br
CF3

DAT
(EC50)
nM
13
49
83
506
42
59
2700

NET
(EC50)
nM
22
63
62
111
44
100
900

SERT
(EC50)
nM
3860
118
1290
120
144
60
190

The only study that compared the MAT profiles of 2-, 3-, and 4-substituted MCAT
analogues was conducted by Cozzi et al.75 who investigated the action of 4-CF3 MCAT
(25) in comparison to its positional isomers (26–27) (Table 5). The releasing potencies of
the three positional isomers at DAT were 30–400 times lower than that of MCAT (3) with
3-CF3 MCAT (27) having the highest potency and 2-CF3 MCAT (26) having the lowest
potency.75 These positional isomers were also 45–135 fold less potent than MCAT as
releasing agents at NET with 4-CF3 MCAT (25) having the highest potency and 3-CF3
MCAT (27) having the lowest potency.75 The pharmacological profiles of these
compounds at SERT are totally different; these compounds were 10 to 21 times more
potent than MCAT as releasing agents except 2-CF3 MCAT (26) which was 2 times less
potent than MCAT.75 The general conclusion here is that substitution of MCAT by a CF3
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group at the 3-, or 4-position of the ring reduces the releasing potency at DAT/NET and
improves it at SERT; 2-CF3 MCAT (26) is the only positional isomer that was less potent
than MCAT at all the three MATs.

Table 5. Releasing potencies of 4-CF3 MCAT (25) and its positional isomers (26–27)
at MATs.75

Compound

R1

R2

R3

MCAT (3)
2-CF3 MCAT (26)
3-CF3 MCAT (27)

H
CF3
H

H
H
CF3

H
H
H

DAT
(EC50)
nM
20
8000
610

NET
(EC50)
nM
20
2200
2700

SERT
(EC50)
nM
4000
8400
380

Methylone (11; Figure 6), a ring-substituted MCAT analogue having its 3-position and 4position linked by a methylenedioxy group, is one of the most common synthetic
cathinones in the clandestine market that acts as a potent releasing agent at all three
MATs.71 It is approximately equipotent at DAT (EC50 = 117 nM) and NET (EC50 = 140 nM),
but is half as potent at SERT (EC50 = 234 nM).71
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2. SAR of reuptake inhibitors
The stereochemistry of derivatized cathinones that primarily act via a reuptake inhibition
mechanism has not been extensively investigated; 71 MDPV (10; Figure 6) and
pyrovalerone (14; Figure 6) are two examples of synthetic cathinones whose individual
isomers were examined for reuptake inhibition at MATs.76,77 Kolanos et al.76 tested the
enantiomers of MDPV in comparison to racemic MDPV and (-)cocaine at MATs (Table
6). S(+)MDPV (S(+)10) was 180- and 73-fold more potent than R(-)MDPV (R(-)10) at DAT
and NET, respectively; however, none of them was active at SERT. Interestingly,
S(+)MDPV (S(+)10) was also 93-fold and 40-fold more potent than (-)cocaine at DAT and
NET, respectively.

Table 6. IC50 values of MPDV (10) and its individual enantiomers in comparison to
(-)cocaine at DAT and NET.76
Compound

DAT
(IC50) nM
5
2
383
199

MDPV (10)
S(+)MDPV (S(+)10)
R(-)MDPV (R(-)10)
(-)cocaine

NET
(IC50) nM
17
10
726
396

Meltzer et al.77 also showed that S(-)pyrovalerone (S(-)14) is approximately 100-fold more
potent than R(+)pyrovalerone (R(+)14) at DAT (Table 7). S(-)Pyrovalerone (S(-)14) was
a potent NET reuptake inhibitor and active as a reuptake inhibitor at SERT, but
R(+)pyrovalerone (R(+)14) lacked affinity at both NET and SERT (Table 7).
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Table 7. IC50 values of pyrovalerone (14) and its individual enantiomers at MATs.77
Compound
Pyrovalerone (14)
S(-)Pyrovalerone (S(-)14)
R(+)Pyrovalerone (R(+)14)
cNot

DAT
(IC50) nM
52
16
1790

NET
(IC50) nM
28
11
c

SERT
(IC50) nM
2780
1070
c

determined because it lacks affinity at the transporters (Ki >10000 nM).

The length of the α-side chain is one of the structural features that determines the function
of derivatized cathinones. The α-methyl group is optimal for the releasing action of
cathinones at DAT; homologation of this group to longer alkyl chains gradually shifts the
compounds from DA releasing agents to DA reuptake inhibitors.71 Kolanos et al.78
investigated the QSAR of α-PVP (13; Figure 6) analogues having variable α-side chains
at DAT to detect the physicochemical properties of the α-side chain that significantly affect
DAT reuptake inhibition. In this study, seven α-PVP analogues were prepared and tested
for DAT reuptake inhibition in comparison to α-PVP (Table 8). A positive correlation was
obtained between the potency of these compounds at DAT and the volume as well as the
lipophilicity of the α-substituent; however, additional compounds should be prepared and
tested to determine whether both the lipophilicity and the volume are important or one of
them is controlling the potency of reuptake inhibition at DAT because of the observed
intercorrelation between the volume and the lipophilicity values of the examined
substituents.78 Conformational restraint of the α-side chain was also investigated in the
same study; but the examined conformationally restricted analogue 35 was 200-fold less
potent than the parent open chain analogue (30) which implies that the compound was
probably locked into the wrong conformation (Table 8).
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Table 8. IC50 values of α-PVP (13) and its analogues at DAT.78

35

28–34
Compound

R

DAT (IC50) nM

α-PVP (13)
28
29
30
31
32
33
34
35

CH2CH2CH3
H
CH3
CH2CH3
CH(CH3)2
CH2(CH2)2CH3
C5H9
C6H11

18
3250
197
63
92
12
17
8
12900

N-Alkylation also controls the function of synthetic cathinones. Increasing the bulk/size of
the N-substituent reduces the releasing potency of cathinone and gradually converts it to
a reuptake inhibitor with tertiary amines having the highest potency as DA reuptake
inhibitors.71 Kolanos et al.79 of our laboratory, examined the potencies of DAT reuptake
inhibition of primary, secondary, and tertiary amine deconstructed analogues of MDPV in
comparison to MDPV (10; Figure 6) (Table 9). The open chain tertiary amine analogue of
MDPV (36) was 5-fold less potent than MDPV and 3-fold more potent than the
corresponding secondary amine analogue 37; further deconstruction to the primary amine
analogue 38 resulted in 14-fold lower potency.
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Table 9. IC50 values of MDPV (10) and its deconstructed analogues at DAT.79

Compound
MDPV (10)
36
37
38

R1
CH3
CH3
H

R2

DAT (IC50) nM

CH3
H
H

135
715
1950
27100

As with releasing agents, the carbonyl group is also relatively unimportant for the actions
of DAT reuptake inhibitors; however, the affinities of derivatized cathinones acting as DAT
reuptake inhibitors are decreased by reduction to a mixture of diastereomeric alcohols.71

The actions of ring-substituted reuptake inhibitors at MATs need to be investigated;
however, there is a general agreement that ring substituents favoring DAT reuptake
inhibition disfavors SERT reuptake inhibition.71

3. SAR of bupropion analogues
Bupropion (1; Figure 1) is a clinically prescribed antidepressant medication that acts as a
selective DAT/NET reuptake inhibitor.3

Musso et al.80 was the first to synthesize bupropion enantiomers and test them in
comparison to racemic bupropion (1; Figure 1); S(+)bupropion (S(+)1) was about twice
30

as potent as R(-)bupropion (R(-)1) as a DAT/NET reuptake inhibitor (Table 10). The same
study also showed that R(-)bupropion (R(-)1) racemizes in vivo which led to loss of
interest in further investigation of individual bupropion isomers.69,80

Table 10. Uptake (approximate) IC50 values of bupropion and its enantiomers at DAT
and NET.69,80
Compound

DAT
(IC50) μM
2
2
4

Bupropion (1)
S(+)Bupropion (S(+)1)
R(-)Bupropion (R(-)1)

NET
(IC50) μM
7
4
11

The most comprehensive SAR study on bupropion analogues at MATs was conducted
by Carroll et al.3 who investigated the therapeutic potential of bupropion analogues as
pharmacotherapies for cocaine addiction. In this study, the test compounds were first
tested in a radioligand binding assay to evaluate the binding affinities of these compounds
at MATs, and only compounds having Ki values <10000 nM were then tested for inhibition
of uptake of [3H] monoamines by hMATs expressed in human embryonic kidney (HEK)
cells.

Extension of the α-methyl group of bupropion to an ethyl, propyl, or butyl group gave
compounds 39–41, respectively which were approximately 25-fold more potent than
bupropion at DAT and equipotent at NET (Table 11). Although further extension of the αside chain to a hexyl group was tolerated at DAT, it resulted in 10-fold lower potency at
NET as shown by the structural transition from compound 41 to compound 42 (Table 11).3
The steric bulk of the α-alkyl group was tolerated at DAT and NET up to a certain limit;
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exceeding this limit led to a total loss of potency at both DAT and NET as shown by the
structural transition from compound 43 to compound 44 (Table 11).3 Bupropion and
bupropion analogues obtained by manipulation of the α-methyl group lacked affinity at
SERT.3

The N-substitution pattern also contributes to the efficacies of bupropion analogues as
reuptake inhibitors at MATs. The N-cyclopropyl (45) and N-cyclobutyl (46) analogues of
bupropion were approximately 4 times more potent than bupropion at DAT (Table 11).3
Interestingly, 45 and 46 had opposite effects at NET. Compound 45 was 5 times less
potent than bupropion at NET.3 In contrast, compound 46 was 5 times more potent than
bupropion as a NET reuptake inhibitor.3 Both 45 and 46 were active as reuptake inhibitors
at SERT, but 46 had 17-fold higher potency than 45.3 Compound 45 is 8-fold selective for
DAT vs NET and 12-fold selective for DAT vs SERT.3 In contrast, compound 46 lacked
selectivity at MATs.3 The N-isopropyl analogue 47, the open chain analogue of 45, was
half as potent as bupropion at DAT and lacked affinity to either NET or SERT; while, the
N-propyl analogue 48, the straight chain analogue of 45, lacked affinity at MATs (Table
11).3 Further extension of the N-cycloalkyl group yielded compound 49 which is almost
equipotent to bupropion (Table 11).3

Tertiary amine analogues were either equipotent or half as potent as bupropion at DAT. 3
At NET, the potencies of reuptake inhibition of these analogues seem to be related to the
steric bulk of R1 and R2; the higher the steric bulk of R1 and R2, the lower the potency of
NET reuptake inhibition.3 As with bupropion, most of them lacked SERT affinity.3
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Table 11. Uptake IC50 values of bupropion (1) and its analogues at MATs.3

39–56

57

Compd

R1

R2

X

Y

1
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

CH3
CH2CH3
CH2CH2CH3
CH2(CH2)2CH3
CH2(CH2)4CH3
CH2CH(CH3)2
CH2CH2C6H11
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3

C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
CH(CH2)2
CH(CH2)3
CH(CH3)2
CH2CH2CH3
CH(CH2)4
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3
C(CH3)3

Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H
Br
F
Me
H
H
H

H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Cl
Br
Me

cNot

59

58
DAT
(IC50)
nM
945
31
33
69
135
440
>10000
265
258
2000
c
980
2310
950
1460
c
2319
1295
c
c
c
c

NET
(IC50)
nM
443
969
472
400
4890
360
>10000
2150
86
c
c
221
8700
6500
c
c
c
c
4100
c
c
c

SERT
(IC50)
nM
c
c
c
c
c
>10000
>10000
3180
185
c
c
c
c
c
c
c
c
2520
c
1240
c
c

determined because it lacks affinity at the transporters.

The nature of the aromatic substituents also affects the actions of bupropion analogues
at MATs. Removal of the aromatic Cl group of bupropion resulted in a 2-fold lower potency
at DAT and approximately 20-fold lower potency at NET as shown by the structural
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transition from 1 to 50.3 Replacement of the Cl group by other halogens such as Br of F
was tolerated at DAT (compounds 51 and 52); however, the potency at NET was
dramatically decreased as in 51 or totally lost as in 52 (Table 11).3 The 3-Me analogue
53 lacked affinity at MATs (Table 11).3

Moving the aromatic substituent from position 3 to position 4 at the ring totally changes
the MAT profiles of these compounds. Shifting the Cl group of bupropion to position 4
converts it to compound 54 that is half as potent at DAT and inactive at NET which renders
the compound a selective DAT reuptake inhibitor (Table 11).3 Compound 55 also lacks
affinity to NET, but it is equipotent to bupropion at DAT and active as a reuptake inhibitor
at SERT which makes it a selective DAT/SERT reuptake inhibitor (Table 11).3 Compound
56, the positional isomer of compound 53, is also inactive at DAT and SERT; however, it
is surprisingly an active NET reuptake inhibitor (Table 11).3

Reduction of des Cl bupropion (50) to compound 57 resulted in loss of affinity to both
DAT and NET, but the compound was still active as a reuptake inhibitor at SERT (Table
11).3

Conformationally restricted analogues of bupropion 58 and 59 were prepared to enhance
the entropic contribution of bupropion to the free energy of binding upon interaction with
MATs; however, both 58 and 59 were inactive at MATs which suggests that these
analogues were essentially locked into the wrong conformations (Table 11).3 Thus,
additional conformationally restricted analogues of bupropion should be prepared and
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tested at MATs to uncover the biologically active conformation or conformations of
bupropion that interacts with DAT and/or NET.

The major drawback of this study is that the utilized assays do not differentiate between
reuptake inhibitors and releasing agents; thus, releasing agents may be misidentified as
reuptake inhibitors. On the other hand, MAT studies in rat brain synaptosomes can
evaluate both reuptake inhibition and releasing potency. Another potential problem with
the current study is that the potency of reuptake inhibition was ruled out based on binding
data; however, the compound may act as a reuptake inhibitor by binding at an allosteric
site of the transporter. This implies that the in vitro MAT profiles of these analogs should
be reinvestigated in rat brain synaptosomes to confirm their actions as reuptake inhibitors
and to provide functional data for low affinity compounds.

Based on currently available data presented above, the following generalizations can be
made about synthetic cathinones as DAT reuptake inhibitors (Figure 10).

It should be realized that the SAR summary shown in Figure 10 is derived from, primarily,
four investigations;3,71,78,79 and these studies employed different techniques. Hence, the
SAR summary (Figure 10) should only be considered as generalizations.
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α

a. As with releasing agents, S-isomers of reuptake inhibitors are generally more potent
than the corresponding R-isomers.
b. The higher the hydrophobic bulk of the α-side chain, the higher the potency of DAT
reuptake inhibition. However, this is only applicable up to a certain limit after which the
potency gradually declines or is totally lost.
c. The potency of DAT reuptake inhibition could be sorted according to the following order:
tertiary amines ≥secondary amines >primary amines.
d. The carbonyl group is not critically important for the potency of these compounds at
DAT.
e. The SAR of ring-substituted analogues has yet to be extensively investigated, but
substitution of 3- and/or 4-positions of the ring by halogens is generally favorable for
reuptake inhibition at DAT.
Figure 10. SAR of synthetic cathinones as DAT reuptake inhibitors.
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III. Specific aims

AIM I. Investigation of the actions of deconstructed bupropion analogues at MATs.
Bupropion (1; Figure 1) and cathinone (2; Figure 1) are structurally similar
aminopropiophenones. What makes bupropion a clinically-employed agent and
cathinone an illegal drug of abuse? The hypothesis is that the actions of bupropion and
cathinone must be related to their MAT profile; however, bupropion and cathinone have
different mechanisms of action at MATs. Bupropion acts as a DAT/NET reuptake inhibitor
whereas cathinone acts as a DAT/NET releasing agent.3,71 Our goal here is to examine
the structural transition from bupropion to cathinone to better understand its actions and
to determine the structural point at which bupropion is converted from a reuptake inhibitor
to a releasing agent (i.e., cathinone).

Deconstruction of bupropion (i.e., a stepwise conversion – or structural transition – of
bupropion to cathinone) by removal and/or simplification of its structural features, one
feature at a time (i.e., 60–64; Figure 11), synthesis of the deconstructed analogues, and
investigation of the actions of these analogues at the three major MATs in rat brain
synaptosomes for selectivity, reuptake inhibition, and/or releasing potency should answer
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our question. S(-)Cathinone (S(-)2; Figure 1) will be used as a control, and SERT data
will be included for comparison.

62

61

1

63

60

64

Figure 11. Deconstructed analogues of bupropion to be investigated.

AIM II. QSAR studies of 2- and 3-substituted MCAT analogues at all three MATs.
Although MCAT is a Schedule I stimulant, new MCAT analogues are continually
appearing on the clandestine market to circumvent prosecution under the Controlled
Substance Analog Enforcement Act.2 Studying the SAR and QSAR of ring-substituted
MCAT analogues at MATs provides the DEA with important information about these
analogues and might predict their future abuse and control. An SAR/QSAR study of 4substituted MCAT analogues at MATs was conducted in our lab in response to the wide
availability of these derivatives on the clandestine market to examine the physicochemical
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properties of 4-position substituents that significantly contribute to the releasing potencies
and selectivities of these compounds at MATs.13

Some 3-substituted MCAT analogues have been recently reported on the clandestine
market;72 3-bromomethcathinone (65; Table 12) and 3-fluoromethcathinone (currently a
US Schedule I substance)81 were seized by Israeli police among other psychoactive
substances in 2009 and were reported by users in online forums to cause stimulant and
empathogenic effects similar to those of 4-methylmethcathinone (12; Figure 6), one of the
most commonly abused synthetic cathinones.72,82,83 The next generation of MCAT
derivatives will probably be 2-substituted MCAT analogues. Here, we propose SAR and
QSAR studies on 2- and 3-substituted MCAT analogues to examine the physicochemical
properties of 2-substituents and 3-substituents important for the actions of these
compounds at MATs and complete the series of ring-substituted MCAT analogues.

For these studies, six (for statistical validity) MCAT analogues having selected
substituents that varied with respect to physicochemical properties (e.g. electronic
character, lipophilicity, size, volume) (Table 12) will be synthesized. Hansch analysis will
be performed between MAT data and individual properties as previously published for
their 4-substituted counterparts.13
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Table 12. MCAT (3) and its 2- and 3-substituted analogues proposed for investigation.

Compound

R1

R2

MCAT (3)
61
65
66
67
68
69
70
71
72
73

H
H
H
H
H
H
Cl
Br
CH3
OCH3
OH

H
Cl
Br
CH3
CF3
OCH3
H
H
H
H
H

The proposed studies will complete a series of ring-substituted analogues of MCAT (3;
Figure 1) to achieve a better understanding of the influence of aryl substituents on the
potency, function, and selectivity of MCAT analogues on MAT action.

The selected 3-position substituents (i.e., H, Cl, Br, CH3, CF3, OCH3) (Table 12) have
different size, lipophilicity, and electronic character which allow the evaluation of the
effects of these parameters on the releasing potencies of 3-MCAT analogues at MATs.
The selected 2-position substituents (i.e., H, Cl, Br, CH3, OH, OCH3) (Table 12) were the
same as the 3-position substituents except the 2-OH substituent which was included
instead of the 2-CF3 substituent, because it might lock MCAT in a particular conformation
by intramolecular hydrogen bonding between the 2-OH and the carbonyl group of 73
without having to create an additional chiral center (Figure 12). Additionally, the MAT
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release data of 2-CF3 MCAT were previously reported by Cozzi et al.75 who evaluated the
potency of the compound in rat brain synaptosomes (the assay routinely used by us in
the current studies); therefore, there was no need to synthesize 2-CF3 MCAT and test it
again at MATs. The 2-substituted MCAT series is particularly important for future
investigations of the effects of the 2-position substituents on the potencies of these
analogues before investigating the actions of conformationally restricted MCAT
analogues (Table 13) to examine the active conformation of MCAT. For example, is the
low potency of 35 (Table 8) due to its incorrect conformation or due to lack of tolerance
for the phenyl 2-substituent?

Figure 12. Compound 73 restricts MCAT in a particular conformation by
intramolecular hydrogen bonding.

Table 13. Conformationally restricted MCAT analogues proposed for future
investigation.

Compound

X

Compound

Y

74
75

CH2
O

76
77

CH2
O
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IV. Results and discussion

A. AIM I. Investigation of the actions of deconstructed bupropion analogues at
MATs
1. Results
a. Chemistry
α-Bromination of 78 provided the required starting material 79 in a good yield which was
then reacted with the appropriate alkylamines in nucleophilic substitution reactions to
yield the target compounds 60 and 61 (Scheme 1). Compound 60 was prepared by
following the procedure reported by Carroll et al.3 for the same compound, but the
unknown HCl salt was prepared instead of the reported fumarate salt because of its higher
water solubility. Synthesis of 60 was relatively easy, because isopropylamine, a sterically
hindered amine, limits the dimerization that may occur during the reaction. In contrast,
synthesis of compound 61 needed special reaction conditions. Synthesis of compound
61 was first attempted by reacting 79 with ethanolic methylamine in benzene at room
temperature for 8 h; however, the yield of the reaction was very low (1%). The low yield
of the reaction could be explained by dimerization. Methylamine is not a sterically
hindered amine which leaves the dimerization uncontrolled during the reaction. Moreover,
the reaction was conducted in an aprotic solvent (benzene) for a long time (8 h) at room
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temperature which further enhances the dimerization reaction. Foley and Cozzi84 reported
opposite reaction conditions for the synthesis of a similar MCAT analogue; they
conducted the reaction in a protic solvent (H2O/EtOH) for a shorter time (2 h) in an ice
bath. Fortunately, the yield of 61 was successfully improved from 1% to 11% by following
these procedures. Compound 61 was unknown at the time of preparation, but Blough et
al.85 subsequently reported its synthesis in a higher yield by using an efficient
protection/deprotection strategy to avoid dimerization.
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Scheme 1. Synthesis of compounds 60, 61, and 62.a

1%
11%

3%
34%

aReagents

and conditions: (i) Br2, AcOH, CH2Cl2, 0 °C; (ii) (a) isopropylamine, 0 °C, 5 h;
(b) HCl/Et2O; (iii) (a) methylamine/EtOH, benzene, room temperature, 8 h; (b)
(COOH)2/Et2O; (iv) (a) methylamine/EtOH, EtOH, H2O, 0 °C, 2 h; (b) HCl/Et2O; (v) NaN3,
acetone, room temperature, 20 h; (vi) (a) Ph3P, THF, H2O, room temperature, 7 days; (b)
(COOH)2/Et2O; (vii) (a) SnCl2, EtOH, room temperature, 12 h; (b) (COOH)2/Et2O.

Nucleophilic substitution of the starting material 79 yielded the intermediate compound
80 which was then used for the synthesis of 62 by two different routes (Scheme 1). In
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route vi, a Staudinger reaction was first attempted, but the yield of the reaction was low
(3%) because of the difficulty experienced during removal of the excess Ph3P (basic
compound) from the reaction mixture by acid/base work up. The yield of 62 was
successfully improved from 3% to 34% by following the procedure reported by Pulici et
al.86 (route vii) who used SnCl4 to reduce des Cl 80 to des Cl 62.

Compound 63 was synthesized from the starting material 81 by a simple nucleophilic
substitution reaction according to the procedure reported by Carroll et al.3 for the same
compound (Scheme 2). The HCl salt of 63 was prepared instead of the reported fumarate
salt to improve the water solubility of the compound, and its melting point was identical to
that of its HCl salt prepared by a different method.84 Additionally, the starting material 81
was used instead of the starting material 79 used in Scheme 1 because of the facial
irritation experienced upon the first exposure to the vapors of 79. Obviously, 81 is less
reactive than 79; therefore, the reaction needed a longer time (3 days).

Scheme 2. Synthesis of compound 63.a

aReagents

and conditions: (i) (a) tert-butylamine, 100 °C, 3 days; (b) HCl/Et2O.
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Synthesis of compound 64 was attempted by 3 routes: routes ii iii, and vii (Scheme 3).
Nucleophilic substitution of the starting material 79 yielded bupropion (1) which was then
utilized for the synthesis of 64 by 2 different routes. In route ii, the procedure reported by
Kolanos et al.79 for reduction of MDPV (10; Figure 6) to des keto MDPV by hydrogenation
in the presence of acid catalysts (HClO4 and AcOH) was first attempted; however, the
reaction did not go to completion after 25 h. Although some bupropion (1) was
successfully reduced to 64, des Cl bupropion and des Cl 64 might have been obtained
as side products because of the high pressure used during the reaction. In addition to the
incomplete reaction and the high number of the side products, the R f values of the
dechlorinated side products were very close to those of the parent compounds; therefore,
it was not encouraging to separate the target compound. An alternative mild reduction
method using Et3SiH as a reducing agent and TFA as a catalyst was also attempted in
route iii, but no change could be observed on TLC after running the reaction for 12 h
which implies that the components of the mixture did not react under these conditions.
The target compound, 64, could not be obtained by the previously mentioned reductive
routes; therefore, a totally different route was used. A reductive amination procedure
reported by Barney et al.87 for the synthesis of hindered amines from ketones using TiCl4
as a Lewis acid and a water scavenger and TEA as a substitute for excess starting amines
was successfully used for synthesis of 64 from the intermediate compound 84 whose
synthesis was attempted by 2 different routes: routes iv and vi. In route iv, a Dakin-West
reaction was first attempted; however, numerous side products were formed as shown by
TLC. In contrast, 84 could be easily synthesized by route vi in which the nitropropene
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intermediate 87, obtained by Henry reaction (route v), was reduced by an Fe/AcOH
mixture.

Scheme 3. Synthesis of compound 64.a

aReagents

and conditions: (i) (a) tert-butylamine, CH3CN, 65 °C, 9 h; (b) HCl/Et2O; (ii)
H2, Pd/C, 45 psi, HClO4, AcOH, room temperature, 25 h; (iii) Et3SiH, TFA, CH2Cl2, room
temperature, 12 h; (iv) (a) CH3COONa, Ac2O, reflux, 48 h; (b) HCl, reflux, 1 h; (v)
CH3COONH4, reflux, 7 h; (vi) Fe, AcOH, 80 °C, 1.5 h; (vii) (a) tert-butylamine, TEA, TiCl4,
CH2Cl2, room temperature, 20 h; (b) NaCNBH3, CH3OH, room temperature, 15 min; (c)
(COOH)2/Et2O.
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b. MAT reuptake studies in rat brain synaptosomes
Effects of bupropion (1) and its deconstructed analogues (60–64) on % uptake of [3H]DA,
[3H]NE, and [3H]5-HT by DAT, NET, and SERT, respectively in rat brain synaptosomes
are shown in Figure 13. Additionally, the uptake IC50, the concentration of the compound
at which half of the maximal uptake inhibition is obtained, values of bupropion (1) and its
deconstructed analogues (60–64) at DAT, NET, and SERT are shown in Table 14. The
bupropion synthesized in Scheme 3 was only used as a synthetic intermediate, but was
not included either in this assay, or the subsequent assay of releasing potencies, because
bupropion was already available in our collaborator’s (Dr. Michael H. Baumann) lab.

The obtained IC50 value for bupropion at DAT (IC50 = 305 nM) in rat brain synaptosomes
(Table 14) is consistent with previously reported IC50 values (IC50 = 550,70 630,89 and 945
nM)3 taking into consideration the differences in species and assay procedures. None of
the deconstructed features majorly contributed to the reuptake inhibition potency of
bupropion at DAT. Compound 60 was only about 2-fold less potent than bupropion.
Compounds 61 and 62 were almost equipotent to bupropion. Compounds 63 and 64 were
only 3 to 4-fold less potent than bupropion. Compounds 60 and 63 were previously
reported by Carroll et al.3 to be half as potent as bupropion at DAT.
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% Uptake

% Uptake

log [60] M

% Uptake

% Uptake

log [1] M

log [61] M

% Uptake

% Uptake

log [62] M

log [64] M

% Uptake

log [63] M

log [S(-)2] M
Figure 13. Effects of bupropion (1) and its deconstructed analogues (60–64) on %
uptake of [3H]DA, [3H]NE, and [3H]5-HT by DAT, NET, and SERT, respectively in rat
brain synaptosomes. S(-)Cathinone (S(-)2) was used as a control.
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Table 14. Uptake IC50 values of bupropion (1) and its deconstructed analogues (60–64)
at MATs. S(-)Cathinone (S(-)2) was used as a control.

Compound
Bupropion (1)
60
61
62
63
64
S(-)Cathinone (S(-)2)

DAT
(IC50) nM
305±55
537±65
342±46
399±87
1308±317
938±130
357±46

NET
(IC50) nM
3715±545
3288±434
290±36
551±50
>10000
2513±420
224±37

SERT
(IC50) nM
>10000
3414±462
1104±79
2779±454
>10000
5113±467
>10000

The potency of bupropion at NET was approximately 10 times lower than its potency at
DAT. The obtained IC50 value for bupropion at NET (IC50 = 3715 nM) in rat brain
synaptosomes also is consistent with the previously reported IC50 values (IC50 = 443,3
1900,70 and 2300 nM)88 taking into consideration the differences in species and assay
procedures. Compounds having bulky substituents at the terminal amine, such as
bupropion (1), 60, 63, and 64, generally favored DAT over NET reuptake inhibition. On
the other hand, compounds having low steric bulk at the terminal amine, such as 61 and
62, showed approximately equal potency at DAT and NET.

Bupropion was inactive at SERT as previously reported by other investigators. 88,89
Compound 63 was also inactive at SERT. The other analogues (60–62, 64) were active
as SERT reuptake inhibitors, but these compounds were 3 to 7 times more potent at DAT.
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c. MAT release studies in rat brain synaptosomes
Effects of bupropion (1) and its deconstructed analogues (60–64) on % release of
[3H]MPP+ via DAT and NET and [3H]5-HT via SERT in rat brain synaptosomes are shown
in Figure 14. Additionally, the release EC50, the concentration of the compound at which
half of the maximal release of a neurotransmitter is obtained, values of bupropion (1) and
its deconstructed analogues (60–64) at DAT, NET, and SERT are shown in Table 15.

Compounds having high steric bulk at the terminal amine, such as bupropion (1), 60, 63,
and 64, were inactive as releasing agents at DAT. In contrast, compounds having low
steric bulk at the terminal amine, such as 61 and 62, were potent DAT releasing agents;
61 and 62 were 6–12 times more potent as DAT releasing agents than as DAT reuptake
inhibitors. The obtained EC50 value for 61 at DAT (EC50 = 29 nM) is consistent with the
EC50 value previously reported by Blough et al.85 (EC50 = 47 nM) who also employed the
same assay for evaluating the releasing potency of the compound.

As with DAT, bupropion (1), 60, 63, and 64 were inactive as releasing agents at NET.
Moreover, compounds 61 and 62 were also potent NET releasing agents; 61 and 62 were
5–7 times more potent as NET releasing agents than as NET reuptake inhibitors.
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% Release

log [60] M
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log [1] M

log [62] M
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log [61] M

log [64] M
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log [63] M
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Figure 14. Effects of bupropion (1) and its deconstructed analogues (60–64) on %
release of [3H]MPP+ via DAT and NET and [3H]5-HT via SERT in rat brain
synaptosomes. S(-)Cathinone (S(-)2) was used as a control.
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Table 15. Releasing potencies of bupropion (1) and its deconstructed analogues (60–
64) at MATs. S(-)Cathinone (S(-)2) was used as a control.a
Compound
DAT
NET
SERT
(EC50) nM (EC50) nM
(EC50) nM
Bupropion (1)
Inactive
Inactive
Inactive
60
Inactive
Inactive
1228±189
61
29±3
40±9
212±32
62
64±10
105±20
567±75
63
Inactive
Inactive
Inactive
64
Inactive
Inactive
Inactive
S(-)Cathinone (S(-)2)
18±4
28±5
4741±1035
aInactive

means that 10000 nM of the test compound could not evoke
>30% of maximal release.

As with DAT and NET, bupropion (1), 63, and 64 were inactive as releasing agents at
SERT; however, 60 was interestingly active as a SERT releasing agent. The potency of
60 as a releasing agent at SERT was approximately 3 times higher than its potency as a
SERT reuptake inhibitor. Additionally, compounds 61 and 62 were also potent SERT
releasing agents, but these compounds were 5–9 times less potent as releasing agents
at SERT than at DAT and NET and 5 times more potent as SERT releasing agents than
as SERT reuptake inhibitors. The obtained EC50 value for 61 at SERT (EC50 = 212 nM) is
also consistent with the EC50 value previously reported by Blough et al.85 (EC50 = 410
nM).

2. Discussion
Bupropion was found to act as a DAT/NET reuptake inhibitor which agrees with the
previous literature. The obtained IC50 value for bupropion at DAT (305 nM) is close to that
of cocaine (IC50 = 198.8 nM)76 which might be responsible for the abuse potential of
bupropion. Some scheduled cathinone derivatives are even more potent than bupropion
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and cocaine at DAT such as α-PVP (13; Figure 6) (IC50 = 18 nM)78 and MDPV (10; Figure
6) (IC50 = 5 nM).76

The potency of reuptake inhibition of the deconstructed bupropion analogues at DAT was
close to that of bupropion; the lowest potency at DAT was obtained in 63 which was only
4 times less potent than bupropion. This implies that none of the deconstructed features
of bupropion is critical for DAT reuptake inhibition. Although bupropion did not act as a
transporter substrate, as shown by lack of releasing potency at all the three transporters,
deconstructed bupropion analogues having small N-alkyl groups (61 and 62) were more
potent as releasing agents than as reuptake inhibitors at the three MATs. This implies
that bupropion could not make it through the transporters because of the steric bulk at its
terminal amine. Thus, reducing the steric bulk at the terminal amine shifted the
mechanism of action of these compounds from reuptake inhibition to substrate-induced
release.

Although 61 and 62 were 5–9 times more potent as releasing agents at DAT/NET over
SERT, they acted as both reuptake inhibitors and releasing agents and had the lowest
selectivity at the three transporters. Methylone (11; Figure 6) and mephedrone (12; Figure
6), commonly abused synthetic cathinones, are also N-methyl cathinone analogues which
act as releasing agents with similar potency at DAT, NET, and SERT.90 Although 60 is an
active SERT releasing agent, it does not act as a DAT/NET substrate. This indicates that
the intermediate steric bulk of the N-isopropyl group of 60 was accommodated only by
SERT but could not be accommodated by either DAT or NET.
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Bulky substituents at the terminal amine favor DAT/SERT selectivity and DAT reuptake
inhibition over DAT-mediated release which is consistent with what have been previously
reported about the pharmacology of synthetic cathinones. 78,79,91 For instance, the steric
bulk at the terminal amine of bupropion (1) enhances its DAT/SERT selectivity and makes
it active as a reuptake inhibitor and inactive as a releasing agent. Similar results were
also observed for NET; for example, the bulky substituents at the terminal amines of 1,
60, 63, and 64 favored NET reuptake inhibition over NET-mediated release. For SERT,
compounds with bulky N-substituents, such as 1, 63, and 64, were inactive or weekly
active as either reuptake inhibitors or releasing agents; however, reducing the steric bulk
at the terminal amine resulted in modest potency of reuptake inhibition.

Although these compounds do not seem to have simple and straight-forward
pharmacological profiles regarding selectivity or molecular mechanism of action, the
obtained information is helpful for determination of the structural features of synthetic
cathinones required for selectivity among the three major MATs and reuptake inhibition
versus transporter-mediated release. Bulky substituents at the terminal amine favor
DAT/NET over SERT reuptake inhibition and DAT/NET reuptake inhibition over
DAT/NET-mediated release which indicates that the bulky amine substituents impede the
transport of these compounds by DAT and NET and renders them reuptake inhibitors
rather than releasing agents. Although compounds with small N-substituents also act as
DAT/NET reuptake inhibitors, they are more potent as releasing agents than as reuptake
inhibitors. Compound 60 is particularly interesting, because it acts as a releasing agent
at SERT and a reuptake inhibitor at DAT and NET. Different molecular mechanisms of
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action for the same compound at MATs were previously reported for N-cyclopropyl
cathinone and N-ethyl cathinone.85,91 The compounds that act as releasing agents at
SERT and reuptake inhibitors at DAT were described as “hybrid” 5-HT releasing
agents/DAT reuptake inhibitors by Blough et al.85 who suggested that this class of
compounds might be therapeutically beneficial for the treatment of drug abuse.
Compounds 1, 63, and 64 evoked the partial release (<30%) of DA, NE and 5-HT, and
compound 60 also partially released DA and NE (Figure 14). Partial release of
neurotransmitters is usually observed for reuptake inhibitors as a result of transporter
blockade and is not transporter-mediated; thus, these compounds were considered
inactive as releasing agents at the corresponding MATs.92 It has been shown that potent
reuptake inhibitors induce 20-30% of the maximal release of the synaptosomal content of
[3H]MPP+ in MAT release studies.93 This was described by Solis et al.93 as “pseudo-efflux”
or “low-efficacy efflux” that occurs as a result of diffusion of [3H]MPP+ from preloaded
synaptosomes in response to transporter blockade. It is noteworthy that some
compounds act as real partial releasers by inducing 50-75% of the maximal release in
MAT release studies.93 It has been suggested that partial releasers have slower rates of
transporter-mediated release; however, the detailed mechanism of partial release has yet
to be investigated.93
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B. AIM II. QSAR studies of 2- and 3-substituted MCAT analogues at all three MATs.
1. Results
a. Chemistry
There was no need to synthesize MCAT (3; Figure 1), because it was already available
in our lab. Additionally, 3-Cl MCAT (61) was previously synthesized as one of the
deconstructed bupropion analogues in Aim I (Scheme 1). The target compounds (65–73)
were prepared as shown in Scheme 4. Compounds (65–72) were synthesized by
following the procedure reported by Blough et al.85 for the synthesis of 3-Cl MCAT (61) in
which an efficient protection/deprotection strategy was utilized to avoid dimerization and
obtain the compound in a good yield. However, it should be noted that compound 68 was
synthesized in collaboration with Tyler Kern (an undergraduate trainee in our lab). αBromopropiophenones 88–95 were first reacted with N-benzylmethylamine in a
nucleophilic substitution reaction to yield the intermediate N-benzyl protected compounds
96–103 which were then deprotected by reflux with 1-chloroethyl chloroformate followed
by reflux in CH3OH to yield the target compounds 65–72 as HCl salts due to expulsion of
HCl gas during the reaction. Compound 73 was obtained from 72 by following the phenolic
O-demethylation procedure reported by Roussey94 who used HI for O-demethylation of a
closely related o-methoxy-2-aminopropiophenone. The synthesis of compound 65 was
previously reported by Foley and Cozzi84 who reacted 88 directly with methylamine to
obtain the compound without using a protection/deprotection strategy; however, the yield
of the reaction was low because of the dimerization that might have occurred during the
reaction. Compound 66 was reported by Power et al.95 who also reacted 89 directly with
methylamine to obtain the compound without using a protection/deprotection strategy.
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The synthesis of compound 67 was previously reported by Brandt et al.96 who followed
the procedure reported by Foley and Cozzi84 to obtain the target compound by reacting
90 directly with methylamine. As with 65 and 66, this procedure also was not followed for
the synthesis of 67. The syntheses of 68, 69, 71, and 72 were previously reported by
Awad et al.97, Ose et al.98, Power et al.95, and Heinzelmann99 respectively. However,
these procedures were not followed, because all of them involved direct interaction
between

methylamine

and

α-bromopropiophenones

without

using

a

protection/deprotection strategy which dramatically affected the yield of the reaction.
Legerlotz100 reported the synthesis of the free base of 73 by reacting α-bromo-obenzoyloxypropiophenone with p-MeC6H4SO2NKMe, an N-methyl acid amide, in a
condensation reaction, followed by saponification of the product to yield the target
compound. However, this procedure was not followed, because 72 was already available
as a starting material for the synthesis of 73 by a simple and convenient phenolic Odemethylation reaction.

58

Scheme 4. Synthesis of compounds 65–73.a

aReagents

and conditions: (i) N-benzylmethylamine, THF, reflux, 18–23 h; (ii) (a) 1chloroethyl chloroformate, CH2Cl2, reflux, 2 h; (b) CH3OH, reflux, 1 h; (c) Et2O, room
temperature, 18 h; (iii) (a) HI, H2O, reflux, 19 h; (b) (COOH)2/EtOH, room temperature, 1
h.
The α-bromopropiophenones 88–90 used in Scheme 4 for the synthesis of 3-substituted
MCAT analogues 65–67 could be readily obtained by α-bromination of the corresponding
propiophenones 104–108 (Scheme 5). The α-bromopropiophenone 91 was also
synthesized by α-bromination of the intermediate propiophenone 108 obtained by
reacting benzonitrile 107 and EtMgBr in a Grignard reaction (Scheme 5).
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Scheme 5. Synthesis of compounds 88–91.a

aReagents

and conditions: (i) Br2, HBr, CH2Cl2, room temperature, 72 h; (ii) Br2, AcOH,
CH2Cl2, room temperature, 12 h; (iii) Br2, AcOH, CH2Cl2, room temperature, 1 h; (iv)
EtMgBr, THF, 40 °C, 3 h; (v) Br2, AlCl3, Et2O, room temperature, 3 h.

The α-bromopropiophenones 92–95 used in Scheme 4 for the synthesis of 2-substituted
MCAT analogues 69–72 were prepared as shown in Scheme 6. The appropriately
substituted aldehydes 109–112 were reacted with EtMgBr in a Grignard reaction to yield
the benzylic alcohols 113–116 which were then oxidized by either PCC or MnO2 to give
the corresponding propiophenones 117–120. α-Bromination of 117–120 provided the
required α-bromopropiophenones 92–95.
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Scheme 6. Synthesis of compounds 92–95.a

aReagents

and conditions: (i) EtMgBr, THF, room temperature, 12 h; (ii) PCC, CH2Cl2,
room temperature, 2 h; (iii) Br2, HBr, CH2Cl2, room temperature, 20 min; (iv) MnO2,
CH2Cl2, reflux, 12 h; (v) Br2, AcOH, Et2O, room temperature, 12 h; (vi) MnO2, Et2O, reflux,
24 h; (vii) Br2, CHCl3, room temperature, 20 min.
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b. MAT release studies in rat brain synaptosomes
Effects of MCAT (3) and its 3-substituted analogues (61, 65–68) on % release of
[3H]MPP+ via DAT and NET and [3H]5-HT via SERT in rat brain synaptosomes are shown
in Figure 15. Additionally, the release EC50 values of these compounds at DAT, NET, and
SERT are shown in Table 16. The releasing potencies of the 2-substituted MCAT
analogues at MATs have yet to be obtained.

All the compounds were active as releasing agents at the three major MATs. The obtained
EC50 values for 61 at DAT (EC50 = 26 nM) and SERT (EC50 = 211 nM) are consistent with
the EC50 values previously reported by Blough et al.85 (DAT EC50 = 47 nM and SERT EC50
= 410 nM) who also employed the same assay for evaluating the releasing potency of the
compound. Compound 66 was previously reported to be approximately equipotent as a
releasing agent at the three MATs (the release (% vehicle) values at the three MATs were
around 60%);101 however, 66 was tested in the literature study only at one concentration
(100 μM) using human MATs expressed in human embryonic kidney (HEK) cells rather
than rat MATs in rat brain synaptosomes which might explain the inconsistency with the
current data (DAT EC50 = 28 nM, NET EC50 = 27 nM, and SERT EC50 = 268 nM). The
EC50 values of 67 at DAT and SERT, 714 and 281 nM, respectively, are consistent with
the EC50 values previously reported by Cozzi et al.75 (DAT EC50 = 610 nM and SERT EC50
= 380 nM) who used the same assay for evaluating the releasing potency of the
compound. Cozzi et al.75 also reported the EC50 value for 67 at NET (EC50 = 2700 nM);
however, it was 10 times higher than the obtained EC50 value (EC50 = 370 nM). The
conflicting results cannot be explained at this time.
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The ranges of SERT EC50/DAT EC50 values (DAT/SERT selectivity) and SERT EC50/NET
EC50 values (NET/SERT selectivity) for these compounds were about 700 and 300,
respectively (Table 16). Methcathinone showed the highest DAT/SERT and NET/SERT
selectivity, whereas, 3-CF3 MCAT showed the highest SERT over DAT and NET
selectivity.
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Figure 15. Effects of MCAT (3) and its 3-substituted analogues (61, 65–68) on %
release of [3H]MPP+ via DAT and NET and [3H]5-HT via SERT in rat brain
synaptosomes.
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Table 16. Releasing potencies of MCAT (3) and its 3-substituted analogues (61, 65–68)
at MATs.

R

Compound

H
Cl
Br
CH3
CF3
OCH3

MCAT (3)
61
65
66
67
68

DAT
(EC50)
nM
21±3
26±4
21±3
28±6
714±73
109±18

NET
SERT
(EC50)
(EC50)
nM
nM
22±3
5853±1250
19±3
211±33
25±4
136±24
27±4
268±25
370±49
281±57
111±12
683±92

SERT
SERT
EC50/DAT EC50/NET
EC50
EC50
278.7
266.1
8.1
11.1
6.5
5.4
9.6
9.9
0.4
0.8
6.3
6.2

c. Correlations
The in vitro biological data at MATs (Table 16) were tested for statistically significant
correlations with a wide range of physicochemical properties (Table 17). The statistically
significant correlations are shown in bold. The physicochemical parameters are either
experimental parameters, such as steric bulk (ES), the electronic character of the aromatic
m-substituents (σm), and lipophilicity (π), or computational parameters, such as volume
(Vol), length (L), minimal width (B1), and maximal width (B5). The physicochemical
parameters of the 3-position substituents utilized in the correlational analysis are shown
in Table 18.13,102,103
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Table 17. Correlational analysis between in vitro MAT data and experimental as well
as computationally-derived physicochemical parameters for the 3-position
substituents (n = 6).a
Physicochemical

Log

Log

Log

Log

Log

property

DAT

NET

SERT

(SERT

(SERT

EC50

EC50

EC50

EC50/DAT

EC50/NET

EC50)

EC50)

Steric bulk (ES)

R = -0.70

R = -0.64

R = 0.68

R = 0.90

R = 0.89

P = 0.12

P = 0.17

P = 0.14

P = 0.01

P = 0.02

Electronic

R = 0.39

R = 0.34

R = -0.59

R = -0.65

R = -0.64

character (σm)

P = 0.45

P = 0.51

P =0.22

P = 0.16

P = 0.18

Lipophilicity (π)

R = 0.19

R = 0.11

R = -0.82

R = -0.67

R = -0.66

P = 0.72

P = 0.84

P = 0.04

P = 0.15

P = 0.15

R = 0.73

R = 0.75

R = -0.68

R = -0.94

R = -0.96

P = 0.10

P = 0.09

P = 0.14

P <0.01

P <0.01

R = 0.24

R = 0.28

R = -0.75

R = -0.65

R = -0.76

P = 0.64

P = 0.59

P = 0.09

P = 0.16

P = 0.11

Minimal width

R = 0.35

R = 0.29

R = -0.9

R = -0.83

R = -0.83

(B1)

P = 0.50

P = 0.57

P = 0.01

P = 0.04

P = 0.04

Maximal width

R = 0.69

R = 0.74

R = -0.46

R = -0.76

R = -0.79

(B5)

P = 0.13

P = 0.09

P = 0.36

P = 0.08

P = 0.06

Volume (Vol)

Length (L)

aBolded

values represent statistically significant correlations.
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Table 18. The physicochemical parameters of the 3-position substituents utilized in
the correlational analysis.13,102,103
R

ES102

σm102

π102

Vol13

L103

B1103

B5103

H
Cl
Br
CH3
CF3
OCH3

1.24
0.27
0.08
0.00
-1.16
0.69

0.00
0.37
0.39
-0.07
0.43
0.12

0.00
0.71
0.86
0.56
0.88
-0.02

150.36
164.43
169.43
166.89
178.40
175.01

2.06
3.52
3.83
3.00
3.30
3.98

1.00
1.80
1.95
1.52
1.98
1.35

1.00
1.80
1.95
2.04
2.61
3.07

It is noteworthy that none of the examined physicochemical parameters correlated with
the individual MAT data except π and B1 values which were correlated with Log SERT
EC50 values (Figure 16).
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Figure 16. Correlations between the in vitro SERT data of 3-substituted MCAT
analogues and π as well as B1 values of the 3-position substituents.

Correlational screening with the experimental parameters showed a positive correlation
between ES values and DAT/SERT as well as NET/SERT selectivity (Table 17).
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The correlations between ES values and DAT/SERT as well as NET/SERT selectivity
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were visualized (Figure 17), and it appears that most of the data points are centrally
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Figure 17. Correlations between the in vitro MAT selectivity data of 3-substituted MCAT
analogues and the steric bulk (ES) values of the 3-position substituents.
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Figure 18. Correlations between the in vitro MAT selectivity data of 3-substituted MCAT
analogues and the volume as well as B1 values of the 3-position substituents.
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clustered with the -CF3 and -H analogues representing extremes. Hence, we examined
other potential relationships using the computationally-derived volume as well as Verloop
parameters (L, B1, and B5) to identify the 3D steric parameters of the 3-position
substituents that might be more likely to control the selectivity of 3-substituted MCATs at
different MATs. Both volume and B1 were negatively correlated with DAT/SERT and
NET/SERT selectivity (Figure 18).

The intercorrelations within the individual in vitro MAT data and physicochemical
parameters had to be investigated to examine the pharmacological trend of these
compounds at different MATs and the significant correlations that might have been
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Figure 19. Intercorrelations within the individual in vitro MAT data of 3-substituted
MCAT analogues and the physicochemical parameters of the 3-position substituents.
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observed as a result of intercorrelated physicochemical parameters. A positive correlation
was observed between the releasing potencies of these compounds at DAT and NET
(Figure 19) yet no significant correlations were obtained between their EC 50 values and
any of the examined parameters (Table 17); DAT/SERT selectivity was also correlated
with NET/SERT selectivity (Figure 19). Minimal width (B1) values were positively
correlated with π values and negatively correlated with ES values (Figure 19).

Interestingly, the in vitro MAT data of the 3-substituted MCAT analogues correlated with
the corresponding data of the 4-substituted MCAT analogues previously reported by
Sakloth74 (Figure 20).

Although the values of the examined physicochemical properties varied across a limited
range, the obtained correlations generally point to the size of the 3-position substituents
as the major determinant of the selectivity of 3-substituted MCAT analogues at MATs.
Additionally, The correlations between the in vitro MAT data of 3- and 4-substituted MCAT
analogues confirm the previously reported finding that the size of the 4-position
substituents also controls the selectivity of 4-substituted MCAT derivatives at MATs.13,73
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Figure 20. Correlations between the in vitro MAT data of 3- and 4-substituted MCAT
analogues.

2. Discussion
A series of MCAT analogues bearing 3-position substituents that varied in their
physicochemical properties, was prepared and examined for their ability to behave as
releasing agents at the MATs. All of the compounds are active (Table 16). With the
exception of the CF3 and OCH3 analogues (67 and 68, respectively), potencies were
nearly identical at DAT and at NET, and showed no selectivity; 67 and 68, although active,
were of reduced potency at DAT and NET. In general, most compounds were less potent
at SERT than at DAT or NET, although 67 was essentially equipotent at all three MATs.
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These data suggest that increasing the volume of the 3-position substituent can be
accommodated by DAT and NET up to a certain limit after which the potency is reduced
as shown in 67 and 68. In contrast, the steric bulk of the 3-position substituents can be
better accommodated by SERT which might explain the DAT/NET over SERT selectivity
of most compounds and the equipotency of 67 at all the three MATs.

The steric bulk of the 3-position substituents of most compounds might be within the limit
accommodated by DAT and NET which might be the reason why none of the examined
physicochemical parameters linearly correlated with DAT or NET data. The lipophilicity
(π) and minimal width (B1) values of the 3-position substituents were negatively
correlated with Log SERT EC50 values; however, only B1 values correlated with
DAT/SERT and NET/SERT selectivity. The steric bulk of the 3-position substituent
controls the selectivity of these compounds for DAT and NET versus SERT. Small
substituents favor DAT/NET over SERT; whereas, large substituents favor SERT over
DAT and NET. These findings indicate that SERT can better accommodate the steric bulk
of the 3-position substituents which is consistent with what has been previously observed
for the deconstructed bupropion analog 60 that was active as a releasing agent at SERT
and inactive as a releasing agent at either DAT or NET (see discussion under bupropion
section). The minimal width (B1) is more likely to be the 3D steric parameter that
dominates the selectivity of these compounds among different MATs, because it was
correlated with both selectivity and Log SERT EC50 values. Although B1 did not correlate
with either DAT or NET data, it might control the selectivity by enhancing the releasing
potency at SERT, but not DAT and NET. The volume and ES values were also correlated
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with selectivity values, but none of them correlated with any of the individual MAT data.
Additionally, the ES and B1 values were intercorrelated which may explain the correlation
between ES and selectivity values. An intercorrelation was also observed between B1 and
π values which explains the correlation between π values and SERT data. The correlation
between DAT and NET data suggests that these compounds might bind similarly at DAT
and NET to release the presynaptic content of DA and NE, respectively and explains the
obtained intercorrelation between DAT/SERT and NET/SERT selectivity.

The

intercorrelation between DAT and NET data may be also explained as a result of their
similar behaviors in response to the steric bulk of the 3-position substituents.

It should be noted, however, that EC50 values for four of the six compounds at DAT were
nearly identical. The same is true at NET. Furthermore, these four compounds displayed
no DAT/NET selectivity. A similar problem is seen with SERT potencies; with the
exception of MCAT, the remaining compounds displayed nearly identical potencies.
Another potential problem in the current QSAR study is that the 3-substituted MCAT
analogs may adopt two different low energy conformations having the 3-position
substituents at opposite sides of the phenyl ring (rotational isomerism). This adds a
second variable to the identity of the 3-position substituents and necessitates the
synthesis of additional six 3-substituted MCAT analogs for statistical significance. As a
consequence, additional 3-substituted MCAT analogs should be synthesized and tested
at MATs to overcome these drawbacks and confirm the current findings.
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The current results are consistent with the QSAR study of the 4-substituted MCAT
analogues previously conducted in our lab which indicated that the steric bulk of the 4position substituents also controls DAT/SERT selectivity; however, this study concluded
that the volume, not the minimal width, of the 4-position substituents is more likely to
contribute to the selectivity of these compounds at different MATs.13,73,74 Interestingly, the
volume values of the 3-position substituents did not significantly correlate with any of the
examined physicochemical parameters. The general conclusion here is that the 3- and 4substituted MCAT analogues might interact similarly at MATs to release the presynaptic
content of neurotransmitters which suggests that the 3-substituted MCAT series may
adjust its orientation to mimic that of the 4-substituted MCAT series in its way through the
transporters; however, this hypothesis has yet to be investigated.
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V. Summary and future directions

Deconstruction of bupropion and evaluation of the in vitro MAT profile of the
deconstructed analogues in comparison to that of bupropion provided us with important
information about the pharmacology of bupropion abuse and expanded our knowledge
about the SAR and molecular mechanisms of action of this class of compounds (synthetic
cathinones). Although bupropion might be viewed as a "synthetic cathinone", it is a
clinically prescribed medication and is not scheduled by the DEA. This study showed that
bupropion is abused, because it is a cathinone derivative which calls for immediate action
to limit the abuse of bupropion. Steric bulk at the terminal amine of these compounds
generally favored reuptake inhibition over transporter-mediated release which implies that
compounds with bulky terminal amine substituents do not readily make it through the
transporters and thus act as reuptake inhibitors rather than releasing agents; bulky
substituents at the terminal amine of these compounds also favored DAT/NET over SERT
reuptake inhibition. Additionally, the data suggest that SERT can accommodate higher
steric bulk at the terminal amine of transporter substrates than DAT and NET. Overall,
the current study provided important pieces of information about the structural features
controlling the selectivity of these compounds at MATs as both reuptake inhibitors and
releasing agents.
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Interestingly, a research article called "khat and mouse game" has been recently
published by Katz et al.104 which implies that DEA and clandestine chemists are playing
a cat and mouse game. Clandestine chemists synthesize new ring-substituted MCAT
derivatives analogous to the scheduled ones to circumvent prosecution under the
Controlled Substance Analog Enforcement Act. Scheduling MCAT pushed the
clandestine chemists to prepare its 4-substituted analogues including mephedrone (4-Me
MCAT) which is one of the most commonly abused synthetic cathinones. 90 Mephedrone
was scheduled among other 4-substituted MCAT analogues; however, 3-substituted
MCAT analogues showed up in the clandestine market of numerous countries as the
second generation of ring-substituted MCAT analogues such as 3-Me MCAT, a positional
isomer of mephedrone, and 3-Br MCAT.72,101,105-113 Consequently, 3-Me MCAT was
scheduled in Israel, USA, and UK, and 3-Br MCAT was scheduled in Israel, Australia,
and New Zealand.72,105 The releasing potencies of 3-Me MCAT and 3-Br MCAT at DAT
are almost the same as that of MCAT which explains the abuse liabilities of these
compounds; 3-Br MCAT was also shown to increase the locomotor activity in mice which
further confirms our in vitro findings.84 2-Me MCAT was reported in the clandestine
market; thus, 2-substituted MCAT analogues are likely to be the final destination of the
clandestine chemists in their trip of MCAT aryl derivatization.110 Studying the
physicochemical properties of the ring-substituents of MCAT that control the releasing
potencies of these compounds at MATs (QSAR studies) set up structural criteria for the
abuse liabilities of these compounds to hopefully stop playing the cat and mouse game.
A QSAR study on the 3-substituted MCAT analogues at MATs is complementary to that
conducted previously, by our laboratory, on the 4-substituted MCAT analogues. The
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general major finding in these studies is that the steric bulk of the 3- and 4-substituents
controls the selectivity of these compounds at the three major MATs. A QSAR study on
the 2-substituted MCAT analogues will complete the ring-substituted MCAT series and is
particularly important to examine the physicochemical properties of the 2-position
substituents important for the actions of these compounds at MATs before synthesis of
conformationally restricted analogues for investigation of the active conformation of
MCAT. For example, why is 35 (Table 8) essentially inactive? Is it because this is the
"wrong" conformation? Or is it because 2-substituents are not tolerated?

77

VI. Experimentals

A Thomas-Hoover melting point apparatus was used for the determination of melting
points, and the obtained values were not corrected. A Bruker ARX 400 MHz spectrometer
was used for recording 1H NMR spectra using tetramethylsilane (TMS) as an internal
standard. Atlantic Microlab Inc. (Norcross, GA) conducted elemental analyses, and the
observed values were within 0.4 % of the calculated values. A Thermo Nicolet iS10 FTIR was used for recording the IR spectra. CombiFlash Companion/TS (Telodyne Isco Inc.,
Lincoln, NE) was used for automated flash chromatography. Silica Gel (230-400 mesh)
was used as an adsorbent, and RediSep Rf Normal-phase Silica Flash Columns
(Teledyne Isco Inc., Lincoln, NE) were used as stationary phases. Thin-layer
chromatography on silica gel GHLF plates (250 μ, 2.5 × 10 cm; Analtech Inc., Newark,
DE) was used for monitoring reactions.

2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one (bupropion) Hydrochloride (1)
Compound 1 was synthesized according to the procedure reported by Wu and Zheng114
for the same compound. tert-Butylamine (1 mL, 10 mmol) was added to a stirred solution
of 2-bromo-1-(3-chlorophenyl)propan-1-one (79) (1.00 g, 4 mmol) in CH3CN (1 mL) and
the reaction mixture was heated in a sealed tube at 65 °C for 9 h. The solvent was

78

evaporated under reduced pressure. Water (25 mL) was added, and the mixture was
acidified with HCl (1N, to pH 1). The aqueous layer was washed with EtOAc (3 x 30 mL),
basified with NaOH (5N, to pH 11) and extracted with Et2O (3 x 30 mL). The combined
organic portion was washed with H2O (20 mL) and brine (20 mL), dried (Na2SO4), and
solvent was evaporated under reduced pressure. A saturated solution of gaseous HCl in
Et2O (5 mL) was diluted with Et2O (495 mL) and added in a dropwise manner at 0 °C (icebath) to the solution of the free base in Et2O (30 mL). The precipitate was collected by
filtration to yield a yellowish white solid which upon recrystallization from CH3OH/Et2O
afforded 0.34 g (31%) of 1 as a white solid: mp 233−234 °C (lit.115 mp 233−234 °C,
CH3OH/Et2O); 1H NMR (DMSO-d6) δ 1.33 (s, 9H, CH3), 1.54 (d, 3H, CH3), 5.31 (t, 1H,
CH), 7.68 (t, 1H, ArH), 7.86 (d, 1H, ArH), 8.17 (d, 1H, ArH), 8.28 (s, 1H, ArH), 8.61 (br s,
1H, NH), 9.61 (d, 1H, NH+).

1-(3-Chlorophenyl)-2-(isopropylamino)propan-1-one Hydrochloride (60)
Compound 60 was prepared by following the procedure reported by Carroll et al.3 for the
same compound, but the unknown HCl salt was prepared instead of the reported
fumarate salt because of its higher water solubility. Isopropylamine (5 mL, 60 mmol) was
added to 2-bromo-1-(3-chlorophenyl)propan-1-one (79) (1.0 g, 4 mmol) and the reaction
mixture was allowed to stir at 0 °C (ice-bath) under an N2 atmosphere for 5 h. The reaction
mixture was diluted with EtOAc (25 mL), filtered, and the collected solid was washed with
EtOAc. The filtrate was washed with H2O (2 x 10 mL). Water (25 mL) was added, and the
mixture was acidified with HCl (1N, to pH 2). The aqueous layer was washed with CH2Cl2
(3 x 30 mL), basified with NH4OH (11%, to pH 11) and extracted with Et2O (3 x 30 mL).
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The combined organic portion was washed with H2O (20 mL) and brine (20 mL), dried
(Na2SO4), and solvent was evaporated under reduced pressure. A saturated solution of
gaseous HCl in Et2O (10 mL) was diluted with Et2O (40 mL) and added in a dropwise
manner at 0 °C (ice-bath) to the solution of the free base in Et2O (40 mL). The precipitate
was collected by filtration to yield a yellowish white solid which upon recrystallization from
EtOH/Et2O afforded 0.3 g (32%) of 60 as a white solid: mp 215−220 °C; 1H NMR (DMSOd6) δ 1.27 (d, 6H, CH3), 1.44 (d, 3H, CH3), 3.29−3.36 (m, 1H, CH), 5.19 (q, 1H, CH), 7.65
(t, 1H, ArH), 7.82 (d, 1H, ArH), 8.07 (d, 1H, ArH), 8.16 (s, 1H, ArH); Anal. Calcd for
(C12H16ClNO·HCl) C, 54.97; H, 6.54; N, 5.34. Found: C, 54.77; H, 6.48; N, 5.36.

1-(3-Chlorophenyl)-2-(methylamino)propan-1-one Hydrochloride (61)
Compound 61 was unknown at the time of preparation, but its synthesis was
subsequently

reported

by

Blough

et

al.85

who

used

a

different

method

(protection/deprotection strategy) for preparation of the same compound. It is noteworthy
that only the HCl salt of 61 is reported in the literature; however, the oxalic acid salt of the
compound has never been reported.

Method A (route iii):
Methylamine (33% in EtOH, 7.5 mL) was added to a stirred solution of 2-bromo-1-(3chlorophenyl)propan-1-one (79) (1.00 g, 4 mmol) in benzene (14 mL), and the reaction
mixture was allowed to stir for 8 h. The solvent was evaporated under reduced pressure.
Water (25 mL) was added, and the mixture was acidified with HCl (1N, to pH 2). The
aqueous layer was washed with CH2Cl2 (3 x 30 mL), basified with NH4OH (11%, to pH
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11) and extracted with Et2O (3 x 30 mL). The combined organic portion was washed with
H2O (10 mL) and brine (20 mL), dried (Na2SO4), and solvent was evaporated under
reduced pressure. A saturated oxalic acid solution in Et2O was added in a dropwise
manner to the solution of the free base in Et2O (30 mL). The precipitate was collected by
filtration to yield a yellowish white solid that was recrystallized from i-PrOH/Et2O to yield
0.01 g (1%) of 61 as a white solid: mp 135 °C; 1H NMR (DMSO-d6) δ 1.42 (d, 3H, CH3),
2.60 (s, 3H, CH3), 5.11 (q, 1H, CH), 7.66 (t, 1H, ArH), 7.83 (d, 1H, ArH), 7.99 (d, 1H, ArH),
8.03 (t, 1H, ArH).

Method B (route iv):
2-Bromo-1-(3-chlorophenyl)propan-1-one (79) (0.80 g, 3 mmol) was dissolved in 95%
EtOH (5 mL) and added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of
methylamine (0.20 g, 6 mmol) in 1:1 EtOH:H2O (2 mL) over 20 min, and the reaction
mixture was allowed to stir for 2 h. The solvent was evaporated under reduced pressure.
Water (25 mL) was added, and the mixture was acidified with HCl (1N, to pH 1). The
aqueous layer was washed with EtOAc (5 x 30 mL), basified with NaOH (5N, to pH 12)
and extracted with EtOAc (3 x 10 mL). The combined organic portion was washed with
H2O (10 mL) and brine (20 mL), dried (Na2SO4), and solvent was evaporated under
reduced pressure. A saturated solution of gaseous HCl in Et2O (5 mL) was diluted with
Et2O (495 mL) and added in a dropwise manner at 0 °C (ice-bath) to the solution of the
free base in Et2O (30 mL). The precipitate was collected by filtration to yield 0.08 g (11%)
of a crude yellowish white solid. Recrystallization of the salt from i-PrOH/Et2O afforded
61 as a white solid: mp 193 °C (lit.85 mp 181−183 °C, CH3OH/EtOAc); 1H NMR (DMSO-
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d6) δ 1.45 (d, 3H, CH3), 2.61 (s, 3H, CH3), 5.20 (q, 1H, CH), 7.66 (t, 1H, ArH), 7.85 (d, 1H,
ArH), 8.00 (d, 1H, ArH), 8.09 (s, 1H, ArH), 9.34 (s, 1H, NH+); Anal. Calcd for
(C10H12ClNO·HCl) C, 51.30; H, 5.60; N, 5.98. Found: C, 51.32; H, 5.54; N, 5.91.

The compounds synthesized by routes iii and iv had the same NMR spectra.

2-Amino-1-(3-chlorophenyl)propan-1-one Hydrogen Oxalate (62)
The synthesis of racemic 62 is not reported in the literature. The individual enantiomers
of 62 were previously synthesized by a special stereoselective Grignard reaction.116
However, the reported route was not followed, because it was impractical and expensive.
It is noteworthy that the compound was characterized only by NMR, and the melting point
is not reported in the literature.

Method A (route vi):
2-Azido-1-(3-chlorophenyl)propan-1-one (80) (0.80 g, 4 mmol) was added to a stirred
solution of triphenylphosphine (1.00 g, 4 mmol) in THF (15 mL) and the reaction mixture
was allowed to stir at room temperature for 7 days. The solvent was evaporated under
reduced pressure. The residue was dissolved in hexane (25 mL) and Et2O (25 mL),
cooled to -18 °C, filtered, and the collected solid was washed with cold hexane. The
solvent was evaporated under reduced pressure. The residue was dissolved in CH3OH
(5 mL). Water (25 mL) was added, and the mixture was cooled to -18 °C, filtered, and the
collected solid was washed with cold H2O. The solvent was evaporated under reduced
pressure. The residue was extracted with Et2O (3 x 20 mL). Water (25 mL) was added,
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and the mixture was acidified with HCl (1N, to pH 2). The aqueous layer was washed with
CH2Cl2 (3 x 20 mL), basified with NH4OH (11%, to pH 11), and extracted with Et2O (3 x
20 mL). The combined organic portion was washed with H2O (10 mL) and brine (10 mL),
dried (Na2SO4), and filtered. A saturated oxalic acid solution in Et2O was added in a
dropwise manner to the filtrate. The precipitate was collected by filtration to yield 0.03 g
(3%) of 62 as a white solid: mp 175−180 °C; 1H NMR (DMSO-d6) δ 1.41 (d, 3H, CH3),
5.15 (q, 1H, CH), 7.65 (t, 1H, ArH), 7.83 (d, 1H, ArH), 8.02 (d, 1H, ArH), 8.09 (s, 1H, ArH).

Method B (route vii):
Stannous chloride dihydrate (1.70 g, 8 mmol) was added in one portion at 0 °C (ice-bath)
to a stirred solution of 80 (0.80 g, 4 mmol) in EtOH (5 mL). The ice bath was removed
and the contents were allowed to stir at room temperature overnight. The solvent was
evaporated under reduced pressure. The reaction mixture was diluted with H 2O (20 mL),
filtered, and the solid was washed with H2O. The filtrate was basified with NaOH (5N, to
pH 12) and extracted with EtOAc (3 x 30 mL). The combined organic portion was washed
with brine (2 x 5 mL), dried (Na2SO4), and solvent was evaporated under reduced
pressure. A saturated oxalic acid solution in Et2O was added in a dropwise manner to the
solution of the free base in Et2O (30 mL). The precipitate was collected by filtration to
yield 0.35 g (34%) of 62 as a white solid: mp 175−180 °C; 1H NMR (DMSO-d6) δ 1.41 (d,
3H, CH3), 5.16 (q, 1H, CH), 7.65 (t, 1H, ArH), 7.83 (d, 1H, ArH), 8.02 (d, 1H, ArH), 8.09
(s, 1H, ArH); Anal. Calcd for (C9H10ClNO·C2H2O4) C, 48.28; H, 4.42; N, 5.12. Found: C,
47.98; H, 4.57; N, 5.24.
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The compounds synthesized by routes vi and vii had the same melting points, NMR
spectra, and Rf values.

2-(N-tert-Butylamino)propiophenone Hydrochloride (63)
Compound 63 was synthesized according to the procedure reported by Carroll et al.3 for
the same compound. tert-Butylamine (9 mL, 86 mmol) was added to 2-chloro-1phenylpropan-1-one (81) (1.0 g, 4 mmol) and the reaction mixture was heated in a sealed
tube at 100 °C for 3 days. The reaction mixture was allowed to cool to room temperature,
filtered, and the collected solid was washed with EtOAc. The filtrate was washed with H 2O
(2 x 10 mL) and extracted with HCl (6N, 3 x 10 mL). The aqueous layer was washed with
EtOAc (10 mL), basified with NaOH (20%, to pH 12), and extracted with EtOAc (3 x 20
mL). The combined organic portion was washed with H2O (10 mL) and brine (10 mL),
dried (Na2SO4), and solvent was evaporated under reduced pressure. The hydrochloride
salt was prepared by adding a saturated solution of gaseous HCl in Et 2O to the solution
of the free base in Et2O. Recrystallization of the salt from CH3OH/Et2O afforded 0.4 g
(25%) of 63 as a white solid: mp 231−235 °C (lit.84 mp 231−235 °C, CH3OH/Et2O); 1H
NMR (DMSO-d6) δ 1.32 (s, 9H, CH3), 1.54 (d, 3H, CH3), 5.31 (q, 1H, CH), 7.65 (t, 2H,
ArH), 7.80 (t, 1H, ArH), 8.22 (d, 2H, ArH), 8.57 (br s, 1H, NH), 9.55 (d, 1H, NH+).

N-tert-Butyl-1-(3-chlorophenyl)propan-2-amine Hydrogen Oxalate (64)
The synthesis of 64 is not reported in the literature. Triethylamine (5.3 mL, 38 mmol) and
tert-butylamine (1.5 mL, 12 mmol) were added at room temperature to a stirred solution
of 84 (1.5 g, 9 mmol) in CH2Cl2 (75 mL) under an N2 atmosphere. A solution of TiCl4 in
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CH2Cl2 (1M, 6.2 mL) was added and the reaction mixture was allowed to stir at room
temperature for 20 h, quenched carefully with a solution of NaCNBH3 (2.3 g, 38 mmol) in
CH3OH (30 mL), and allowed to stir for 15 min. The mixture was basified with NaOH (5N,

to pH 13) and extracted with EtOAc (2 x 150 mL). The combined organic portion was
dried (Na2SO4) and evaporated under reduced pressure. A saturated oxalic acid solution
in Et2O was added in a dropwise manner to the solution of the free base in Et2O (30 mL).
The precipitate was collected by filtration to yield a yellowish white solid that was
recrystallized from CH3OH/Et2O to yield 0.9 g (31%) of 64 as a white solid: mp 195 °C; 1H
NMR (DMSO-d6) δ 1.13 (d, 3H, CH3), 1.37 (s, 9H, CH3), 2.69−2.75 (m, 1H, CH2),
3.18−3.22 (m, 1H, CH2), 3.59−3.64 (m, 1H, CH), 7.28 (d, 1H, ArH), 7.33−7.40 (m, 2H,
ArH), 7.44 (s, 1H, ArH); Anal. Calcd for (C13H20ClN·C2H2O4) C, 57.05; H, 7.02; N, 4.44.
Found: C, 56.92; H, 6.90; N, 4.35.

1-(3-Bromophenyl)-2-(methylamino)propan-1-one Hydrochloride (65)
The synthesis of 65 was previously reported by Foley and Cozzi84 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.2 mL, 2.0 mmol) was added at room temperature
to a stirred solution of 96 (0.28 g, 0.8 mmol) in anhydrous CH2Cl2 (5 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (5 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a brown solid that was recrystallized from i-PrOH/Et2O to yield 0.09 g
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(39%) of 65 as a pale brown solid: mp 185 °C (lit.84 mp 178−181 °C, i-PrOH/Et2O). 1H
NMR (DMSO-d6) δ 1.42 (d, 3H, CH3), 2.57 (s, 3H, CH3), 5.18 (d, 1H, CH), 7.57 (t, 1H,
ArH), 7.95 (d, 1H, ArH), 8.02 (d, 1H, ArH), 8.19 (t, 1H, ArH), 9.16 (br s, 1H, NH), 9.62 (br
s, 1H, NH+).

2-(Methylamino)-1-(3-methylphenyl)propan-1-one Hydrochloride (66)
The synthesis of 66 was previously reported by Power et al.95 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.9 mL, 8 mmol) was added at room temperature
to a stirred solution of 97 (1.1 g, 4 mmol) in anhydrous CH2Cl2 (25 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (25 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a pale green solid that was recrystallized from CH3OH/EtOAc to yield
0.6 g (70%) of 66 as a grey solid: mp 193−195 °C (lit.95 mp 188−190 °C). 1H NMR (DMSOd6) δ 1.42 (d, 3H, CH3), 2.39 (s, 3H, CH3), 2.57 (s, 3H, CH3), 5.13 (q, 1H, CH), 7.45−7.57
(m, 2H, ArH), 7.81−7.85 (m, 2H, ArH).

2-(Methylamino)-1-(3-(trifluoromethyl)phenyl)propan-1-one Hydrochloride (67)
The synthesis of 67 was previously reported by Brandt et al.96 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.71 mL, 7 mmol) was added at room temperature
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to a stirred solution of 98 (1.04 g, 3 mmol) in anhydrous CH2Cl2 (20 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (5 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a yellowish white solid that was recrystallized from CH3OH/EtOAc to
yield 0.62 g (71%) of 67 as a white solid: mp 171 °C (lit.96 mp 163.5−165 °C). 1H NMR
(DMSO-d6) δ 1.54 (d, 3H, CH3), 2.70 (s, 3H, CH3), 5.38 (d, 1H, CH), 7.96 (t, 1H, ArH),
8.22 (d, 1H, ArH), 8.42−8.43 (m, 2H, ArH), 9.28 (br s, 1H, NH), 9.76 (br s, 1H, NH+).

2-(Methylamino)-1-(3-methoxyphenyl)propan-1-one Hydrochloride (68)
The synthesis of 68 was previously reported by Awad et al.97 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. It is noteworthy that the compound was characterized only by MS and NMR,
and the melting point is not reported in the literature. 1-Chloroethyl chloroformate (0.88
mL, 8 mmol) was added at room temperature to a stirred solution of 99 (1.15 g, 4 mmol)
in anhydrous CH2Cl2 (25 mL). The stirred reaction mixture was heated at reflux for 2 h,
cooled to room temperature, and concentrated under reduced pressure. The residue was
dissolved in CH3OH (25 mL), heated at reflux for 1 h, cooled to room temperature, and
evaporated to dryness under reduced pressure. The residue was stirred in Et 2O for 18 h.
The precipitate was collected by filtration to yield a yellowish white solid that was
recrystallized from EtOH to yield 0.60 g (70%) of 68 as a white solid: mp 174−175 °C. 1H
NMR (DMSO-d6) δ 1.42 (d, 3H, CH3), 2.57 (s, 3H, CH3), 3.83 (s, 3H, CH3), 5.17 (q, 1H,
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CH), 7.29–7.33 (m, 1H, ArH), 7.49–7.54 (m, 2H, ArH), 7.60–7.63 (m, 1H, ArH), 9.34 (br
s, 2H, NH2+); Anal. Calcd for (C11H15NO2·HCl·0.7 H2O) C, 54.52; H, 7.24; N, 5.78. Found:
C, 54.63; H, 7.20; N, 5.85.

1-(2-Chlorophenyl)-2-(methylamino)propan-1-one Hydrochloride (69)
The synthesis of 69 was previously reported by Ose et al.98 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.8 mL, 7.3 mmol) was added at room temperature
to a stirred solution of 100 (1.07 g, 3.7 mmol) in anhydrous CH2Cl2 (23 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (23 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a green solid that was recrystallized from CH3OH/EtOAc to yield 0.30
g (35%) of 69 as a white solid: mp 172−174 °C (lit.98 mp 159−161 °C). 1H NMR (DMSOd6) δ 1.37 (d, 3H, CH3), 2.66 (s, 3H, CH3), 4.99 (q, 1H, CH), 7.55−7.59 (m, 1H, ArH), 7.66
(d, 2H, ArH), 7.90 (d, 1H, ArH), 9.36 (br s, 2H, NH2+); Anal. Calcd for (C10H12ClNO·HCl)
C, 51.30; H, 5.60; N, 5.98. Found: C, 51.08; H, 5.51; N, 5.94.

1-(2-Bromophenyl)-2-(methylamino)propan-1-one Hydrochloride (70)
The synthesis of 70 is not reported in the literature. 1-Chloroethyl chloroformate (0.25 mL,
2.30 mmol) was added at room temperature to a stirred solution of 101 (0.38 g, 1.14
mmol) in anhydrous CH2Cl2 (7 mL). The stirred reaction mixture was heated at reflux for
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2 h, cooled to room temperature, and concentrated under reduced pressure. The residue
was dissolved in CH3OH (7 mL), heated at reflux for 1 h, cooled to room temperature, and
evaporated to dryness under reduced pressure. The residue was stirred in Et 2O for 18 h.
The precipitate was collected by filtration to yield a yellowish white solid that was
recrystallized from CH3OH/EtOAc to yield 0.09 g (29%) of 70 as a white solid: mp
172−174 °C; 1H NMR (DMSO-d6) δ 1.36 (d, 3H, CH3), 2.66 (s, 3H, CH3), 4.98 (q, 1H, CH),
7.54−7.62 (m, 2H, ArH), 7.82−7.84 (m, 1H, ArH), 7.88 (d, 1H, ArH), 9.44 (br s, 2H, NH2+);
Anal. Calcd for (C10H12BrNO·HCl) C, 43.12; H, 4.70; N, 5.03. Found: C, 43.21; H, 4.84;
N, 4.91.

2-(Methylamino)-1-(2-methylphenyl)propan-1-one Hydrochloride (71)
The synthesis of 71 was previously reported by Power et al.95 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.65 mL, 6 mmol) was added at room temperature
to a stirred solution of 102 (0.79 g, 3 mmol) in anhydrous CH2Cl2 (18 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (18 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a yellow solid that was recrystallized from CH3OH/EtOAc to yield 0.33
g (53%) of 71 as a white solid: mp 160 °C (lit.95 mp 163−165 °C). 1H NMR (DMSO-d6) δ
1.36 (d, 3H, CH3), 2.44 (s, 3H, CH3), 2.62 (s, 3H, CH3), 5.06 (q, 1H, CH), 7.39−7.42 (m,
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2H, ArH), 7.53−7.57 (m, 1H, ArH), 7.89−7.92 (m, 1H, ArH), 9.24 (br s, 1H, NH), 9.61 (br
s, 1H, NH+).

1-(2-Methoxyphenyl)-2-(methylamino)propan-1-one Hydrochloride (72)
The synthesis of 72 was previously reported by Heinzelmann99 However, the literature
procedure was not followed in order to avoid dimerization and improve the yield of the
reaction. 1-Chloroethyl chloroformate (0.8 mL, 8 mmol) was added at room temperature
to a stirred solution of 103 (1.04 g, 4 mmol) in anhydrous CH2Cl2 (22 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (22 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The precipitate was collected
by filtration to yield a yellow solid that was recrystallized from CH3OH/EtOAc to yield 0.59
g (70%) of 72 as a white solid: mp 184 °C (lit.99 mp 175−177 °C). 1H NMR (DMSO-d6) δ
1.40 (d, 3H, CH3), 2.60 (s, 3H, CH3), 3.96 (s, 3H, CH3), 4.83 (q, 1H, CH), 7.13 (t, 1H, ArH),
7.28 (d, 1H, ArH), 7.70 (t, 1H, ArH), 7.80 (d, 1H, ArH), 9.22 (br s, 2H, NH2+).

1-(2-Hydroxyphenyl)-2-(methylamino)propan-1-one Hydrogen Oxalate (73)
Legerlotz100 reported the synthesis of the free base of 73. However, this procedure was
not followed, because 72 was already available as a starting material for the synthesis of
73 by a simple and convenient phenolic O-demethylation reaction. Hydriodic acid (57%
in H2O, 5 mL) was added at room temperature to 72 (0.16 g, 0.7 mmol) under an N2
atmosphere. The stirred reaction mixture was heated at reflux for 19 h, cooled to room
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temperature, quenched by addition of NaOH (5N, to pH 13), and extracted with EtOAc (3
x 20 mL). The combined organic portion was washed with brine (10 mL), dried (Na2SO4),
and evaporated to dryness under reduced pressure. Oxalic acid (0.06 g, 0.7 mmol) was
dissolved in EtOH (20 mL) and added at room temperature to a stirred solution of the free
base in EtOH (5 mL), and the reaction mixture was allowed to stir at room temperature
for 1 h. The solvent was evaporated under reduced pressure, and the residue was stirred
in Et2O overnight. The precipitate was collected by filtration to yield a green solid that was
recrystallized from CH3OH/EtOAc to yield 0.04 g (19%) of 73 as a grey solid: mp 128 °C;
1H

NMR (DMSO-d6) δ 1.44 (s, 3H, CH3), 2.60 (s, 3H, CH3), 4.87 (br s, 1H, CH), 6.96 (t,

1H, ArH), 7.07 (d, 1H, ArH), 7.53 (t, 1H, ArH), 7.80 (d, 1H, ArH); Anal. Calcd for
(C10H13NO2·C2H2O4·0.5 H2O) C, 51.80; H, 5.80; N, 5.03. Found: C, 51.70; H, 5.54; N,
5.25.

2-Bromo-1-(3-chlorophenyl)propan-1-one (79)
Compound 79 was synthesized according to the procedure reported by Blough et al.85 for
the same compound. Acetic acid (80%, 10 drops) was added at 0 °C (ice-bath) to a stirred
solution of 1-(3-chlorophenyl)propan-1-one (78) (2.0 g, 12 mmol) in CH2Cl2 (20 mL).
Bromine (99.5%, 1 mL) was diluted with CH2Cl2 (10 mL) and added in a dropwise manner
until the color of bromine persisted. The reaction mixture was washed with 5N NaOH (5
mL), saturated Na2S2O3 (5 mL), H2O (10 mL), brine (10 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield 2.4 g (83%) of 79 as a pale green
oil; 1H NMR (CDCl3) δ 1.83 (d, 3H, CH3), 5.15 (q, 1H, CH), 7.36 (t, 1H, ArH), 7.49 (d, 1H,
ArH), 7.82 (d, 1H, ArH), 7.92 (s, 1H, ArH).

91

2-Azido-1-(3-chlorophenyl)propan-1-one (80)
The synthesis of 80 is not reported in the literature. Sodium azide (0.4 g, 6 mmol) was
added to a stirred solution of 2-bromo-1-(3-chlorophenyl)propan-1-one (79) (1.0 g, 4
mmol) in acetone (8 mL), and the reaction mixture was allowed to stir at room temperature
for 20 h. The solvent was evaporated under reduced pressure. Diethyl ether (20 mL) was
added, and the mixture was washed with H2O (5 mL), brine (5 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield 0.8 g (95%) of 80 as a yellow oil.

1-(3-Chlorophenyl)propan-2-one (84)
Compound 84 was previously synthesized through a Dakin-West reaction.117 The
literature procedure was first followed, but 84 could not be obtained. Therefore, the
following procedures were used for the synthesis of 84. A solution of 87 (3.1 g, 15 mmol)
in glacial acetic acid (22 mL) was added in portions at 80 °C (water-bath) to a stirred
solution of iron powder (9.2 g, 166 mmol) in glacial acetic acid (37 mL) under an N2
atmosphere. The reaction mixture was allowed to stir at 80 °C for 1.5 h, cooled to room
temperature, diluted with H2O (300 mL), filtered, and the filtrate was extracted with CH2Cl2
(3 x 60 mL). The combined organic portion was washed with 10% NaOH (2 x 75 mL),
brine (60 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to
yield 1.5 g (57%) of 84 as a yellow oil. 1H NMR (CDCl3) δ 2.10 (s, 3H, CH3), 3.61 (s, 2H,
CH2), 7.00−7.02 (m, 1H, ArH), 7.13 (s, 1H, ArH), 7.18−7.20 (m, 2H, ArH).
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1-(3-Chlorophenyl)-2-nitropropene (87)
Compound 87 was synthesized according to the procedure reported by Blough et al.85 for
the same compound. 3-Chlorobenzaldehyde (85) (4.8 g, 34 mmol) was added at room
temperature to a stirred solution of ammonium acetate (2.6 g, 34 mmol) in nitroethane
(86) (50 mL) under an N2 atmosphere. The stirred reaction mixture was heated at reflux
for 7 h, cooled to room temperature, and concentrated under reduced pressure. The
residue was dissolved in a solution of CH2Cl2 in Et2O (10%, 30 mL), washed with 1N HCl
(10 mL), brine (20 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield a crude product which was purified by column chromatography (silica
gel; hexane/EtOAc; 95:5) to afford 3.1 g (46%) of 87 as a yellow oil. 1H NMR (CDCl3) δ
2.37 (s, 3H, CH3), 7.22−7.24 (m, 1H, ArH), 7.32−7.34 (m, 3H, ArH), 7.93 (s, 1H, CH).

2-Bromo-1-(3-bromophenyl)propan-1-one (88)
Compound 88 was synthesized according to the procedure reported by Carroll et al. 118
for the same compound. Hydrobromic acid (62%, 5 drops) was added at room
temperature to a stirred solution of 1-(3-bromophenyl)propan-1-one (104) (0.36 g, 2
mmol) in CH2Cl2 (10 mL). Bromine (99.5%, 0.1 mL) was diluted with CH2Cl2 (20 mL) and
added in a dropwise manner over 20 min, and the reaction mixture was allowed to stir at
room temperature for 72 h. The solvent was evaporated under reduced pressure. The
residue was dissolved in CH2Cl2 (20 mL), washed with 5N NaOH (5 mL), saturated
Na2S2O3 (5 mL), H2O (10 mL), brine (5 mL), dried (Na2SO4), and evaporated to dryness
under reduced pressure to yield a crude product which was purified by column
chromatography (silica gel; hexane/EtOAc; 95:5) to afford 0.24 g (49%) of 88 as a yellow
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oil. 1H NMR (CDCl3) δ 1.83 (d, 3H, CH3), 5.14 (q, 1H, CH), 7.30 (t, 1H, ArH), 7.65 (d, 1H,
ArH), 7.87 (d, 1H, ArH), 8.08 (t, 1H, ArH).

2-Bromo-1-(3-methylphenyl)propan-1-one (89)
Compound 89 was synthesized according to the procedure reported by Boss et al. 119 for
the same compound. Acetic acid (80%, 10 drops) was added at room temperature to a
stirred solution of 1-(3-methylphenyl)propan-1-one (105) (1.0 g, 7 mmol) in CH2Cl2 (5 mL).
Bromine (99.5%, 0.35 mL) was diluted with CH2Cl2 (35 mL) and added in a dropwise
manner over 20 min, and the reaction mixture was allowed to stir at room temperature
overnight. The mixture was washed with H2O (4 x 10 mL), brine (2 x 10 mL), dried
(Na2SO4), and evaporated to dryness under reduced pressure to yield 1.4 g (91%) of 89
as a brown oil. 1H NMR (CDCl3) δ 1.83 (d, 3H, CH3), 2.36 (s, 3H, CH3), 5.22 (q, 1H, CH),
7.28−7.35 (m, 2H, ArH), 7.73−7.76 (m, 2H, ArH).

2-Bromo-1-(3-(trifluoromethyl)phenyl)propan-1-one (90)
Compound 90 was synthesized according to the procedure reported by Dally et al.120 for
the same compound. Acetic acid (80%, 10 drops) was added at room temperature to a
stirred solution of 1-(3-(trifluoromethyl)phenyl)propan-1-one (106) (1.0 g, 5 mmol) in
CH2Cl2 (5 mL). Bromine (99.5%, 0.26 mL) was diluted with CH2Cl2 (26 mL) and added in
a dropwise manner over 20 min, and the reaction mixture was allowed to stir at room
temperature for 1 h. The mixture was washed with H2O (3 x 20 mL), brine (2 x 20 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield 1.3 g (94%)
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of 90 as a brown oil. 1H NMR (CDCl3) δ 1.93 (d, 3H, CH3), 5.27 (q, 1H, CH), 7.64 (t, 1H,
ArH), 7.85 (d, 1H, ArH), 8.21 (d, 1H, ArH), 8.28 (s, 1H, ArH).

2-Bromo-1-(3-methoxyphenyl)propan-1-one (91)
Compound 91 was synthesized according to the procedure reported by Carroll et al. 121
for the same compound. Bromine (0.6 mL, 11.3 mmol) was added in a dropwise manner
at room temperature to a stirred solution of 108 (1.85 g, 11.3 mmol), and AlCl3 (0.75 g,
0.6 mmol) in anhydrous Et2O (40 mL). The contents were allowed to stir for 3h at room
temperature. The reaction was worked up by addition of saturated NaHCO 3 (40 mL) and
washed with brine (3 x 10 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield 1.8 g as a crude clear oil. The crude oil was purified by column
chromatography to yield 1.78 g (90%) of 91 as a clear oil. 1H NMR (CDCl3) δ 1.90 (d, 3H,
CH3), 3.87 (s, 3H, CH3), 5.28 (q, 1H, CH), 7.11–7.15 (m, 1H, ArH), 7.36–7.40 (m, 1H,
ArH), 7.41–7.55 (m, 2H, ArH).

2-Bromo-1-(2-chlorophenyl)propan-1-one (92)
Compound 92 was synthesized according to the procedure reported by Kalendra and
Sickles122 for the same compound. Bromine (99.5%, 1 drop) and hydrobromic acid (48%,
1 drop) were added at room temperature to a stirred solution of 117 (0.95 g, 5.6 mmol) in
CH2Cl2 (3 mL). The stirred reaction mixture was heated at 35 °C until the color of bromine
was discharged. After cooling, bromine (99.5%, 0.3 mL) was diluted with CH2Cl2 (30 mL)
and added in a dropwise manner over 20 min until the color of bromine persisted. The
mixture was washed with H2O (3 x 10 mL), brine (10 mL), dried (Na2SO4), and evaporated
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to dryness under reduced pressure to yield 1.32 g (94%) of 92 as a yellow oil. 1H NMR
(CD3COCD3) δ 1.73 (d, 3H, CH3), 5.34 (q, 1H, CH), 7.32−7.36 (m, 1H, ArH), 7.42−7.43
(m, 2H, ArH), 7.56−7.59 (m, 1H, ArH).

2-Bromo-1-(2-bromophenyl)propan-1-one (93)
Compound 93 was synthesized according to the procedure reported by Elson et al.123 for
the same compound. Bromine (99.5%, 1 drop) and hydrobromic acid (48%, 1 drop) were
added at room temperature to a stirred solution of 118 (0.53 g, 2.5 mmol) in CH2Cl2 (2
mL). The stirred reaction mixture was heated at 35 °C until the color of bromine was
discharged. After cooling, bromine (99.5%, 0.13 mL) was diluted with CH2Cl2 (13 mL) and
added in a dropwise manner over 20 min until the color of bromine persisted. The mixture
was washed with H2O (3 x 10 mL), brine (10 mL), dried (Na2SO4), and evaporated to
dryness under reduced pressure to yield 0.67 g (92%) of 93 as a yellow oil. 1H NMR
(CD3COCD3) δ 1.74 (d, 3H, CH3), 5.32 (q, 1H, CH), 7.32−7.41 (m, 2H, ArH), 7.54 (d, 1H,
ArH), 7.60 (d, 1H, ArH).

2-Bromo-1-(2-methylphenyl)propan-1-one (94)
Compound 94 was synthesized according to the procedure reported by Kalendra and
Sickles122 for the same compound. Acetic acid (100%, 3 drops) was added at room
temperature to a stirred solution of 119 (0.67 g, 4.5 mmol) in Et2O (10 mL). Bromine
(99.5%, 0.25 mL) was diluted with Et2O (25 mL), and added in a dropwise manner over
20 min, and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was evaporated under reduced pressure. Water (20 mL) was added, and the
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mixture was extracted with CH2Cl2 (3 x 40 mL). The combined organic portion was
washed with brine (10 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield 0.90 g (87%) of 94 as a yellow oil. 1H NMR (CDCl3) δ 1.82 (d, 3H, CH3),
2.43 (s, 3H, CH3), 5.12 (q, 1H, CH), 7.18−7.22 (m, 2H, ArH), 7.33 (t, 1H, ArH), 7.54 (d,
1H, ArH).

2-Bromo-1-(2-methoxyphenyl)propan-1-one (95)
Compound 95 was synthesized according to the procedure reported by Heinzelmann99
for the same compound. Bromine (99.5%, 0.32 mL) was diluted with CHCl3 (32 mL) and
added in a dropwise manner over 20 min to a stirred solution of 120 (1.03 g, 6 mmol) in
CHCl3 (10 mL) until the color of bromine persisted. The mixture was washed with H2O (3
x 10 mL), brine (10 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield 1.25 g (82%) of 95 as a yellow oil. 1H NMR (CDCl3) δ 1.79 (d, 3H, CH3),
3.86 (s, 3H, CH3), 5.45 (q, 1H, CH), 6.90 (d, 1H, ArH), 6.96 (t, 1H, ArH), 7.42 (t, 1H, ArH),
7.66 (d, 1H, ArH).

2-(Benzyl(methyl)amino)-1-(3-bromophenyl)propan-1-one (96)
The synthesis of 96 is not reported in the literature. N-Benzylmethylamine (0.6 mL, 5
mmol) was added at room temperature to a stirred solution of 88 (0.67 g, 2 mmol) in
anhydrous THF (10 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
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crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
95:5) to afford 0.28 g (36%) of 96 as a yellow oil. 1H NMR (CDCl3) δ 1.22 (d, 3H, CH3),
2.11 (s, 3H, CH3), 3.56 (s, 2H, CH2), 4.13 (q, 1H, CH), 7.16−7.26 (m, 6H, ArH), 7.59 (d,
1H, ArH), 7.82 (d, 1H, ArH), 8.09 (t, 1H, ArH).

2-(Benzyl(methyl)amino)-1-(3-methylphenyl)propan-1-one (97)
The synthesis of 97 is not reported in the literature. N-Benzylmethylamine (1.6 mL, 12
mmol) was added at room temperature to a stirred solution of 89 (1.4 g, 6 mmol) in
anhydrous THF (25 mL). The stirred reaction mixture was heated at reflux for 23 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
95:5) to afford 1.1 g (67%) of 97 as a yellow oil. 1H NMR (CDCl3) δ 1.30 (d, 3H, CH3),
2.21 (s, 3H, CH3), 2.39 (s, 3H, CH3), 3.65 (s, 2H, CH2), 4.29 (q, 1H, CH), 7.23−7.34 (m,
7H, ArH), 7.76−7.79 (m, 2H, ArH).

2-(Benzyl(methyl)amino)-1-(3-(trifluoromethyl)phenyl)propan-1-one (98)
Compound 98 was synthesized according to the procedure reported by Miyano et al.124
for the same compound. N-Benzylmethylamine (1.25 mL, 10 mmol) was added at room
temperature to a stirred solution of 90 (1.31 g, 5 mmol) in anhydrous THF (20 mL). The
stirred reaction mixture was heated at reflux for 18 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in EtOAc (20 mL),
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washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine (5 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield a crude product which was
purified by column chromatography (silica gel; hexane/EtOAc; 95:5) to afford 1.04 g
(70%) of 98 as a yellow oil. 1H NMR (CDCl3) δ 1.21 (d, 3H, CH3), 2.12 (s, 3H, CH3), 3.57
(s, 2H, CH2), 4.18 (q, 1H, CH), 7.09−7.31 (m, 5H, ArH), 7.50 (t, 1H, ArH), 7.75 (d, 1H,
ArH), 8.10 (d, 1H, ArH), 8.30 (s, 1H, ArH).

2-(Benzyl(methyl)amino)-1-(3-methoxyphenyl)propan-1-one (99)
The synthesis of 99 is not reported in the literature. N-Benzylmethylamine (1.9 mL, 15
mmol) was added at room temperature to a stirred solution of 91 (1.78 g, 7 mmol) in
anhydrous THF (40 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (3 x 10 mL), dried (Na2SO4),
and evaporated to dryness under reduced pressure to yield a crude product which was
purified by column chromatography (silica gel; hexane/EtOAc; 95:5) to afford 1.15 g
(64%) of 99 as a clear oil. 1H NMR (CDCl3) δ 1.30 (d, 3H, CH3), 2.22 (s, 3H, CH3), 3.64
(s, 2H, CH2), 3.84 (s, 3H, CH3), 4.29 (q, 1H, CH), 7.08–7.12 (m, 1H, ArH), 7.20–7.36 (m,
6H, ArH), 7.55–7.59 (m, 2H, ArH).

2-(N-Benzyl-N-methylamino)-1-(2-chlorophenyl)propan-1-one (100)
The synthesis of 100 is not reported in the literature. N-Benzylmethylamine (1.4 mL, 10.8
mmol) was added at room temperature to a stirred solution of 92 (1.32 g, 5.3 mmol) in
anhydrous THF (22 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
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to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
90:10) to afford 1.07 g (70%) of 100 as a yellow oil. 1H NMR (CD3COCD3) δ 1.13 (d, 3H,
CH3), 2.04 (s, 3H, CH3), 3.46 (s, 2H, CH2), 4.19 (q, 1H, CH), 6.87−6.89 (m, 2H, ArH),
7.04−7.05 (m, 3H, ArH), 7.25−7.29 (m, 1H, ArH), 7.34−7.39 (m, 3H, ArH).

2-(N-Benzyl-N-methylamino)-1-(2-bromophenyl)propan-1-one (101)
The synthesis of 101 is not reported in the literature. N-Benzylmethylamine (0.6 mL, 4.6
mmol) was added at room temperature to a stirred solution of 93 (0.67 g, 2.3 mmol) in
anhydrous THF (10 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
90:10) to afford 0.38 g (50%) of 101 as a yellow oil. 1H NMR (CD3COCD3) δ 1.13 (d, 3H,
CH3), 2.06 (s, 3H, CH3), 3.48 (s, 2H, CH2), 4.19 (q, 1H, CH), 6.88−6.91 (m, 2H, ArH),
7.04−7.06 (m, 3H, ArH), 7.26−7.38 (m, 3H, ArH), 7.52−7.54 (m, 1H, ArH).

2-(N-Benzyl-N-methylamino)-1-(2-methylphenyl)propan-1-one (102)
The synthesis of 102 is not reported in the literature. N-Benzylmethylamine (1 mL, 8
mmol) was added at room temperature to a stirred solution of 94 (0.90 g, 4 mmol) in
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anhydrous THF (16 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
80:20) to afford 0.79 g (74%) of 102 as a yellow oil. 1H NMR (CDCl3) δ 1.21 (d, 3H, CH3),
2.16 (s, 3H, CH3), 2.36 (s, 3H, CH3), 3.54 (s, 2H, CH2), 4.08 (q, 1H, CH), 7.04−7.06 (m,
2H, ArH), 7.11−7.19 (m, 5H, ArH), 7.28 (t, 1H, ArH), 7.44 (d, 1H, ArH).

2-(N-Benzyl-N-methylamino)-1-(2-methoxyphenyl)propan-1-one (103)
The synthesis of 103 is not reported in the literature. N-Benzylmethylamine (1.33 mL, 10
mmol) was added at room temperature to a stirred solution of 95 (1.25 g, 5 mmol) in
anhydrous THF (21 mL). The stirred reaction mixture was heated at reflux for 18 h, cooled
to room temperature, and concentrated under reduced pressure. The residue was
dissolved in EtOAc (20 mL), washed with saturated NaHCO3 (5 mL), H2O (5 mL), brine
(5 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a
crude product which was purified by column chromatography (silica gel; hexane/EtOAc;
80:20) to afford 1.04 g (71%) of 103 as a yellow oil. 1H NMR (CDCl3) δ 1.20 (d, 3H, CH3),
2.12 (s, 3H, CH3), 3.50 (q, 2H, CH2), 3.68 (s, 3H, CH3), 4.33 (q, 1H, CH), 6.85 (d, 1H,
ArH), 6.90−6.98 (m, 3H, ArH), 7.10−7.14 (m, 3H, ArH), 7.34−7.42 (m, 2H, ArH).
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1-(3-Methoxyphenyl)propan-1-one (108)
Compound 108 was synthesized according to the procedure reported by Mateos et al.125
for the same compound. Ethylmagnesium bromide (19 mL, 19 mmol) was added in a
dropwise manner at room temperature to a stirred solution of 3-methoxybenzonitrile (107)
(2 mL, 15 mmol) in anhydrous THF (25 mL). The contents were allowed to stir for 60 min
at room temperature then heated to 40 °C for 3 h, cooled to room temperature and left to
stir overnight. The reaction was quenched by the careful addition of H 2O (15 mL) and
saturated aqueous solution of NH4Cl (24 mL). The organic portion was extracted with
ethyl acetate (5 x 10 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield 2 g as a crude clear oil. The crude oil was purified by column
chromatography to yield 1.85 g (93%) of 108 as a clear oil. 1H NMR (CDCl3) δ 1.22 (t, 3H,
CH3), 2.99 (q, 2H, CH2), 3.85 (s, 3H, CH3), 7.08–7.14 (m, 1H, ArH), 7.34–7.38 (m, 1H,
ArH), 7.49–7.50 (m, 2H, ArH).

1-(2-Chlorophenyl)propan-1-ol (113)
Compound 113 was synthesized according to the procedure reported by Inamoto et al.126
for the same compound. 2-Chlorobenzaldehyde (109) (2.00 g, 14.2 mmol) was dissolved
in anhydrous THF (24 mL) and added in a dropwise manner at 0 °C (ice-bath) to a stirred
solution of ethylmagnesium bromide (1M in THF, 24 mL) under an N2 atmosphere, and
the reaction mixture was allowed to stir at room temperature overnight. Water (10 mL)
was added, and the solvent was evaporated under reduced pressure. The residue was
dissolved in CH2Cl2 (35 mL), washed with 2N HCl (40 mL), H2O (10 mL), brine (10 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a crude
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product which was purified by column chromatography (silica gel; hexane/EtOAc; 90:10)
to afford 1.75 g (72%) of 113 as a colorless oil. 1H NMR (CDCl3) δ 0.92 (t, 3H, CH3),
1.62−1.82 (m, 2H, CH2), 1.87 (d, 1H, OH), 4.98−5.02 (m, 1H, CH), 7.10−7.14 (m, 1H,
ArH), 7.19−7.27 (m, 2H, ArH), 7.46−7.49 (m, 1H, ArH).

1-(2-Bromophenyl)propan-1-ol (114)
Compound 114 was synthesized according to the procedure reported by Matsuda et al.127
for the same compound. 2-Bromobenzaldehyde (110) (2.00 g, 10.8 mmol) was dissolved
in anhydrous THF (18 mL) and added in a dropwise manner at 0 °C (ice-bath) to a stirred
solution of ethylmagnesium bromide (1M in THF, 18 mL) under an N2 atmosphere, and
the reaction mixture was allowed to stir at room temperature overnight. Water (10 mL)
was added, and the solvent was evaporated under reduced pressure. The residue was
dissolved in CH2Cl2 (35 mL), washed with 2N HCl (40 mL), H2O (10 mL), brine (10 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a crude
product which was purified by column chromatography (silica gel; hexane/EtOAc; 90:10)
to afford 1.07 g (46%) of 114 as a colorless oil. 1H NMR (CDCl3) δ 0.94 (t, 3H, CH3),
1.59−1.82 (m, 2H, CH2), 1.90 (d, 1H, OH), 4.93−4.96 (m, 1H, CH), 7.03−7.07 (m, 1H,
ArH), 7.26 (t, 1H, ArH), 7.43−7.48 (m, 2H, ArH).

1-(2-Methylphenyl)propan-1-ol (115)
Compound 115 was synthesized according to the procedure reported by Power et al.95
for the same compound. 2-Methylbenzaldehyde (111) (2.1 g, 17.5 mmol) was dissolved
in anhydrous THF (10 mL) and added in a dropwise manner at 0 °C (ice-bath) to a stirred
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solution of ethylmagnesium bromide (1M in THF, 30 mL) under an N2 atmosphere, and
the reaction mixture was allowed to stir at room temperature overnight. Water (15 mL)
was added, and the solvent was evaporated under reduced pressure. The residue was
dissolved in CH2Cl2 (30 mL), washed with 2N HCl (10 mL), H2O (10 mL), brine (10 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield a crude
product which was purified by column chromatography (silica gel; hexane/EtOAc; 90:10)
to afford 2.0 g (76%) of 115 as a yellow oil. 1H NMR (CDCl3) δ 0.91 (t, 3H, CH3), 1.66−1.73
(m, 2H, CH2), 2.27 (s, 3H, CH3), 4.80 (t, 1H, CH), 7.05−7.18 (m, 3H, ArH), 7.39 (d, 1H,
ArH).

1-(2-Methoxyphenyl)propan-1-ol (116)
Compound 116 was synthesized according to the procedure reported by Tomich et al.128
for the same compound. 2-Methoxybenzaldehyde (112) (2.38 g, 17.5 mmol) was
dissolved in anhydrous THF (10 mL) and added in a dropwise manner at 0 °C (ice-bath)
to a stirred solution of ethylmagnesium bromide (1M in THF, 30 mL) under an N2
atmosphere, and the reaction mixture was allowed to stir at room temperature overnight.
Water (15 mL) was added, and the solvent was evaporated under reduced pressure. The
residue was dissolved in CH2Cl2 (35 mL), washed with 2N HCl (40 mL), H2O (10 mL),
brine (10 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure to
yield a crude product which was purified by column chromatography (silica gel;
hexane/EtOAc; 90:10) to afford 2.18 g (75%) of 116 as a colorless oil. 1H NMR (CDCl3) δ
0.88 (t, 3H, CH3), 1.71−1.79 (m, 2H, CH2), 2.45 (d, 1H, CH), 3.78 (s, 3H, CH3), 4.71 (q,
1H, CH), 6.81 (d, 1H, ArH), 6.88 (d, 1H, ArH), 7.16 (t, 1H, ArH), 7.19−7.23 (m, 1H, ArH).
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1-(2-Chlorophenyl)propan-1-one (117)
Compound 117 was synthesized according to the procedure reported by Inamoto et al.126
for the same compound. Pyridinium chlorochromate (2.42 g, 11.2 mmol) was added at
room temperature to a stirred solution of 113 (1.75 g, 10.3 mmol) in anhydrous CH2Cl2
(55 mL), and the reaction mixture was allowed to stir at room temperature for 2 h. The
reaction mixture was diluted with Et2O (35 mL), filtered, and the filtrate was evaporated
to dryness under reduced pressure to yield a crude product which was purified by column
chromatography (silica gel; hexane/EtOAc; 90:10) to afford 0.95 g (55%) of 117 as a pale
yellow oil. 1H NMR (CD3COCD3) δ 1.00 (t, 3H, CH3), 2.81 (q, 2H, CH2), 7.27−7.32 (m, 1H,
ArH), 7.35−7.37 (m, 2H, ArH), 7.41−7.44 (m, 1H, ArH).

1-(2-Bromophenyl)propan-1-one (118)
Compound 118 was synthesized according to the procedure reported by Mahendar et
al.129 for the same compound. Pyridinium chlorochromate (1.19 g, 5.5 mmol) was added
at room temperature to a stirred solution of 114 (1.07 g, 5.0 mmol) in anhydrous CH2Cl2
(25 mL), and the reaction mixture was allowed to stir at room temperature for 2 h. The
reaction mixture was diluted with Et2O (17 mL), filtered, and the filtrate was evaporated
to dryness under reduced pressure to yield a crude product which was purified by column
chromatography (silica gel; hexane/EtOAc; 90:10) to afford 0.53 g (50%) of 118 as a pale
yellow oil. 1H NMR (CDCl3) δ 1.15 (t, 3H, CH3), 2.86 (q, 2H, CH2), 7.19−7.23 (m, 1H, ArH),
7.29 (d, 2H, ArH), 7.53 (d, 1H, ArH).
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1-(2-Methylphenyl)propan-1-one (119)
Synthesis of 119 was reported by Power et al.95 who used PCC as an oxidizing agent;
however, the literature procedure was not followed to avoid the messy and tedious work
up procedures required for removal of the brown tar produced by PCC during the reaction.
Manganese dioxide (11.60 g, 133 mmol) was added at room temperature to a stirred
solution of 115 (2.00 g, 13 mmol) in CH2Cl2 (100 mL), and the reaction mixture was
allowed to stir at room temperature for 18 h. The stirred reaction mixture was heated at
reflux overnight, cooled to room temperature, filtered, and the filtrate was evaporated to
dryness under reduced pressure to yield a crude product which was purified by column
chromatography (silica gel; hexane/EtOAc; 80:20) to afford 0.67 g (34%) of 119 as a pale
yellow oil. 1H NMR (CDCl3) δ 1.12 (t, 3H, CH3), 2.42 (s, 3H, CH3), 2.84 (q, 2H, CH2),
7.16−7.19 (m, 2H, ArH), 7.27−7.31 (m, 1H, ArH), 7.54−7.56 (m, 1H, ArH).

1-(2-Methoxyphenyl)propan-1-one (120)
Compound 120 was previously synthesized by methylation of its phenolic analog.130
However, the reported route was not followed, because it was impractical and expensive.
Manganese dioxide (23.64 g, 272 mmol) was added at room temperature to a stirred
solution of 116 (2.18 g, 13 mmol) in Et2O (650 mL). The stirred reaction mixture was
heated at reflux for 24 h, cooled to room temperature, filtered, and the filtrate was
evaporated to dryness under reduced pressure to yield a crude product which was
purified by column chromatography (silica gel; hexane/EtOAc; 90:10) to afford 1.03 g
(48%) of 120 as a colorless oil. 1H NMR (CDCl3) δ 1.09 (t, 3H, CH3), 2.92 (q, 2H, CH2),
3.83 (s, 3H, CH3), 6.88−6.94 (m, 2H, ArH), 7.37 (t, 1H, ArH), 7.60 (d, 1H, ArH).

106

MAT reuptake and release studies
MAT reuptake and release studies were conducted in our collaborator’s (Dr. Michael H.
Baumann) lab. Male Sprague−Dawley rats weighing 250−350 g were purchased from
Harlan Laboratories, Frederick, MD. Every three rats were housed in one cage and
provided with unlimited food and water and a 12 h light/dark cycle. The Association for
the Assessment and Accreditation of Laboratory Animal Care accredited the animal
facilities. The experimental procedures were conducted according to the guidelines of the
Institutional Animal Care and Use Committee and the National Institutes of Health on care
and use of animal subjects in research. All chemicals and reagents utilized in these
assays were purchased from Sigma-Aldrich, St. Louis, MO, except [3H]dopamine,
[3H]norepinephrine, and [3H]5-HT which were obtained from PerkinElmer, Shelton, CT.

MAT reuptake studies
Narcosis by CO2 was used for euthanizing rats. The rat brains were then used to obtain
the synaptosomes from rat caudate tissue for DAT assays and rat whole brain minus
caudate and cerebellum for NET and SERT assays. [3H]Dopamine (5 nM),
[3H]norepinephrine (10 nM), and [3H]5-HT (5 nM) were used for assessment of transport
activity at DAT, NET, and SERT, respectively. Unlabeled blockers were included to inhibit
the uptake of [3H]transmitter by transporters other than the transporter of interest to
ensure the selectivity of the assays. Tissue suspension (100 μL) was added to Krebsphosphate buffer (900 μL) in which the test compound and the tritiated neurotransmitter
were dissolved. Rapid vacuum filtration by Whatman GF/B filters was used for termination
of assays, followed by liquid scintillation counting to quantify the retained radioactivity.
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Dose−response curves were constructed by recording the uptake of tritiated
neurotransmitters in the absence and presence of eight different concentrations of the
test compound. The data were expressed as the mean % of maximal uptake ± SD for 3
experiments conducted in triplicate. GraphPad Prism (v. 6.0; GraphPad Scientific, San
Diego, CA) was used for statistical analyses, and nonlinear regression analysis was
followed to calculate the IC50 values for uptake inhibition.

MAT release studies
Narcosis by CO2 was used for euthanizing rats. The rat brains were then used to obtain
the synaptosomes from striatum for DAT assays and rat whole brain minus striatum and
cerebellum for NET and SERT assays. The radiolabeled substrate used in SERT assays
was [3H]5-HT (5 nM). On the other hand, [3H]1-methyl-4-phenylpyridinium ([3H]MPP+) (9
nM) was used as a radiolabeled substrate in DAT and NET assays. The vesicular uptake
of substrates was blocked by using buffers containing 1 μM reserpine. Unlabeled blockers
were included to inhibit the uptake of [3H]MPP+ or [3H]5-HT by transporters other than the
transporter of interest to ensure the selectivity of the assays. Preloaded synaptosomes
were prepared by incubating synaptosomes with Krebs-phosphate buffer containing the
radiolabeled substrate for 1 h. Preloaded synaptosomes (850 μL) were added to the test
compound (150 μL). Rapid vacuum filtration by Whatman GF/B filters was used for
termination of assays, followed by liquid scintillation counting to quantify the retained
radioactivity. The percent of maximum release of tritiated neurotransmitters, the release
induced by 100 nM tyramine for SERT and 10 nM tyramine for DAT and NET, was
calculated for every test compound concentration. Dose−response curves were
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constructed by incubating the preloaded synaptosomes in the absence and presence of
eight different concentrations of the test compound. The data were expressed as the
mean % of maximal release ± SD for 3 experiments conducted in triplicate. The
compounds producing lower than 30% of maximal release were considered inactive.
GraphPad Prism (v. 6.0; GraphPad Scientific, San Diego, CA) was used for statistical
analyses, and nonlinear least-squares curve fitting was followed to calculate the EC50
values.
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